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Executive Summary 
 
This Commission argues that a combination of poor quality science, unclear funding models, 
unrealistic hopes, and unscrupulous private clinics threatens regenerative medicine’s social 
“licence to operate”. If regenerative medicine is to shift from mostly small-scale bespoke 
experimental interventions into routine clinical practice, it will require significant rethinking 
of the social contract that supports such research and clinical practice in the public arena.  
 
For decades, stem cell therapy was predominantly limited to bone marrow transplantation 
for haematological diseases and epidermis transplantation for large burns. Tissue 
engineering and gene therapy faced huge challenges on their way to clinical translation – a 
situation that began to change only at the end of the 1990s. Recent years have seen an 
exponential growth in experimental therapies, broadly defined as “regenerative medicine”, 
entering the clinical arena. Results vary from unequivocal clinical efficacy for previously 
incurable and devastating diseases to (more frequently) a modest or null effect. The reasons 
for these widely different outcomes are starting to emerge. 
 
At this stage in their evolution, these experimental therapies (which include, but are not 
limited to cell and gene therapy, tissue engineering and new generation drugs) are 
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necessarily financially expensive.  Rigorous and costly “clinical grade” procedures must be 
followed in the development of medicinal products (involving cells, genetically manipulated 
cells, viral vectors or biomaterials with or without cells), often produced in a very limited 
run. The cost of developing sufficiently high quality trials means that only wealthier 
countries are able to fund them. While there are massive public investments in this field 
internationally, they do not carry guaranteed commercial returns. Compared to conventional 
drug development, they follow a highly uncertain route to market. Moreover, new therapies 
expose patients to risks, some of which are difficult to predict even with inbuilt safeguards.  
 
Despite the relatively small number of clinical successes, there remains great optimism and 
excitement about the potential impact of this field. This, in turn, has led to gaps between 
people’s expectations that new therapies should be available, often inflated by media reports, 
and the realities of translating regenerative technologies into the clinical practice. The same 
environment is also permissive of one-off ‘compassionate’ applications and poorly controlled 
trials. Indeed, there is an international growth of poorly regulated clinics that appeal to 
desperate patients and their families, who, in the absence of reliable clinical knowledge from 
trials, cannot be adequately informed to assess the risks and benefits.  
 
These ethical and governance issues pose a challenge to scientists in engaging with the 
public, the press, and decision-making bodies in different national health systems. Political 
agendas may not coincide with the public good. In poorly-regulated states, the authorization 
of a novel therapy may be politically attractive, even where efficacy is unconfirmed, and the 
burden for taxpayers could deprive other patients of established and effective therapies. 
These are difficult challenges to address and solve. The Commission recommends that the 
solution lies in a coordinated strategy with four pillars: better science, better funding 
models, better governance, better public and patient engagement. 
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Panel 1 
Key Messages and recommendations 
 
Key messages 
- Current research is hampered by reduced funding for excellent basic research, 
frequent absence of strong pre-clinical evidence, poor trial design, and poor and 
inconsistent reporting, particularly of non-randomised trials. 
- Evidence of the cost effectiveness of regenerative medicine is exceedingly sparse and 
more is needed. The rarity of many conditions for which regenerative medicine is 
indicated entails that there may be significant ongoing uncertainty surrounding the 
expected effectiveness and cost-effectiveness.  
- Understanding patients’ and broader publics’ expectations is key for maintaining 
public trust in cell and gene therapies. The current gap between public expectations 
and the realities of translating regenerative technologies threatens regenerative 
medicine’s social “licence to operate”. 
- Cell and gene therapies require a strong governance framework oriented towards the 
public interest. Given the uncertainty and contested nature of the current social 
contract for these therapies, it is a mistake to think that the answer is more science 
with less regulation.  
 
Recommendations 
1. Pre-clinical work in animals should be conducted as rigorously as clinical 
experimentation. Evaluation and reporting of trial results should be extremely 
detailed to allow appropriate moves to Phase IIb and beyond.  
2. Institutions should invest more in the development of “Clinician Scientists” and 
reduce the burden of this “double career”; this would facilitate the transition from 
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pre-clinical to clinical work (1). Moreover more academic GMP facilities should 
be created to make trials affordable also for academics. 
3. Research into how cell and gene therapies can become cost-effective and scalable 
should be a priority. The incorporation of wider societal benefits from new 
therapies within the appraisal framework should be considered in tandem with 
current work in this area more broadly.  
4. An international register of cell and biological experimental interventions should 
be created, and sustainable funding secured for it, possibly within the EMA and 
FDA, but with a careful process of review to guarantee the scientific soundness of 
trials.  
5. Policy should be developed by the International Committee of Medical Journal 
Editors (ICJME) so that cell and biological therapies will not be published unless 
trials have been registered in the proposed international register. 
6. The initial review for every experimental therapy  should consider the relevant 
social and regulatory context.  
7. Researchers and others involved in funding, publishing and communicating stem 
cell research should integrate some responsibility for public dialogue into their 
research, engagement and communication plans. Such plans should include 
appropriate use of  social media and internet forums. 
 
Introduction 
 
In his Foreword to the Nuffield Council on Bioethics Report, Emerging Biotechnologies: 
Technology, Choice, and the Public Good, Michael Moran (who chaired its Working Party on 
Emerging Biotechnologies) wrote: 
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When we began to look at the field of emerging biotechnologies . . . their sheer breadth 
became apparent and their differences perhaps more important than their similarities. The 
only cross-cutting issue common to all emerging biotechnologies is indeed that they are 
‘emerging’. Therefore, we have focused precisely on this process of emergence, and on the 
conditions that shape it. We are concerned, above all, with how reflection on decisions 
concerning biotechnology innovation can produce outcomes better aligned with the public 
good.1  
 
In the few years since that report, biotechnology has already changed markedly, but the 
problem remains: when so much of what the near future holds emerges quickly and often 
unexpectedly, how do we make sound judgments about what is best for the public good? It is 
often difficult for policy to keep up. Policy makers may not always fully consider the social 
consequences, and may well have different objectives from those doing the science. How do 
we ensure the knowledge gained from publically funded research yields public benefit? With 
the palpable sense of (probably disproportionate) public excitement and expectation, around 
stem cell therapies, it is the scope, rather than the scale, of the health benefits they promise 
that makes them significant.  
 
Because of this promise, there are a number of significant challenges that must be addressed 
if stem cell- and regenerative medicine is to deliver sustainable, significant and equitable 
benefits. The most urgent challenge may arise from the current combination of the ‘political 
economy of hope’ invested in stem cell therapies, 2-4 the relative lack of established therapies, 
and the persistence of a significant cross-border market in untested and probably 
inefficacious therapies. 5  The great risk of the current situation is highlighted by recent case 
of Vannoni in Italy, in which the Stamina Foundation succeeded in obtaining direct 
authorization from the Italian government, rather than through the country’s Regulatory 
Authorities. 6 The risk of this goes deeper than possible harm to individuals. When cases like 
this arise, the long term credibility of stem cell research and scientific integrity are also at 
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stake. It is vital, therefore, that a broad reflection on the ethics and governance of stem cell 
research and regenerative medicine plays an intrinsic role in their development, if their 
"licence to operate" is to be maintained. Within a global context, issues of ethics and 
inequalities may apply more strongly to Europe and the USA, with doctrinal and ideological 
dimensions, 'culturally specific meaning in different global locales', and cross-cultural 
differences that have 'hitherto unseen moral and ethical complexities' holding an equivalent 
relevance. 7, 8  
 
Fortunately, there is now general agreement of a need to discuss and scrutinize technologies 
‘upstream’ – that is, when they are still at a relatively early stage, rather than waiting until 
they are ready to be deployed.9 As discussed in this Commission’s sction on Public 
Engagement and Trust, guidelines from the International Society of Stem Cell Research 
(ISSCR) and from the International Society of Cell Therapy (ISCT) now define the criteria for 
a correct and timely translation of stem cell research to clinics, and identify “unproven 
therapies” as a real danger for patients.10-12 In principle, such upstream engagement fosters 
open dialogue amongst scientists and different publics. It brings uncertainties and risks, as 
well as potential benefits of the new technologies out into the open, and allows the results of 
these discussions to shape frameworks for anticipatory governance. In practice, however, the 
question of how technologies might be scrutinised upstream when their outcome can only be 
evaluated in patients - must also be considered. This is indicative of the need for a ‘reflexive’ 
science policy, rather than one constituted as a ‘reflex’ regulatory response to developments 
in this field. 13 
 
Ethical and governance challenges will shift over time as stem cell and regenerative therapies 
move from the experimental to the routine. Early engagement can also influence choices 
about where to focus research and development efforts. Research funding for cell therapies is 
money that is not spent on other potential therapeutic advances. It is legitimate to ask 
whether the investment made in these therapies will provide a justifiable return in terms of 
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future health benefits. While it is difficult to identify promising lines of research early on, 
those with responsibility for allocating research funds must do just this.  Where research 
does lead to a therapy becoming a routine part of clinical practice, issues of cost and access 
will become increasingly salient – once therapies are available, political and social pressures 
come to bear that are often not exerted when allocating research funding. It is possible that 
most regenerative medicine therapies, even once approved and established, may be 
significantly less cost effective than other therapies funded in healthcare systems, as is 
explored in more detail later. To fund these therapies would potentially result in other – 
more cost effective – therapies having to be limited elsewhere, leading to foregone health, 
greater morbidity and avoidable mortality for those patients who lose out. Yet, if successful, a 
cell/gene or tissue engineering therapy could be economically viable as a single intervention, 
rather than a costly life-long treatment. Ethical issues also arise in denying a truly life-saving 
therapy to a patient because it is considered too expensive.  
 
Questions about access to treatment in all healthcare systems are choices about priorities. 
The biggest question for the future will not, therefore, concern whether regenerative 
medicine will be able to provide significant health benefits, but whether the cost of those 
benefits is worth paying. Provided efficacy is demonstrated, it might be argued that a 
justification of high costs could be that there is something exceptional about the type of 
health benefits being provided. For example, the severity of the diseases for which these 
treatments are used − or the importance in the long-term of significantly extending powers 
of bodily regeneration beyond those that are 'natural' − might justify funding them over 
currently more cost effective therapies. But any such analysis must be reflexive: new abilities 
to repair the body may now seem extraordinary, but may come over time to seem as 
unexceptional as blood transfusions do now. There must be a balance between trying to 
identify lines of research that promise effective treatments, and allowing researchers the 
freedom to pursue questions where the answers may not show benefit for many years, if ever.  
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In order to contextualise the ethical and economic challenges described above and detailed 
further in this Commission, and to understand the potential for therapeutic benefit, we will 
first describe the scientific underpinnings of key technologies involved, their origins, and 
possible trajectories in mainstream healthcare.  As these topics are already broad, cell and 
gene therapy in cancer research will not be covered here. As a huge and expanding area in its 
own right, its main goal is to destroy cancer tissue, rather than in the regeneration of a 
diseased one. 
 
 
Cell and Gene Therapy  
 
Cell and Gene Therapy can be broadly defined as medical procedures in which cells or genes 
represent the medicinal product (see box 1). As with any definition, this type of generic 
description cannot offer a complete insight and may also mask inaccuracies; we have, 
therefore, attempted to illustrate and expand upon this description through the examples 
provided below.  
 
Cell therapy:  haematopoietic and epithelial stem cell transplantation. 
In cell therapy, cells are isolated from a donor and transplanted into a recipient (Figure 1). 
The donor and the recipient may be the same (autologous transplantation) or different 
individuals (allogeneic transplantation). Attempts to mobilise a patient’s own (endogenous) 
cells (usually with bioactive molecules such as growth factors, chemokines, or hormones) 
and direct them to where they may exert a beneficial effect in a given pathology (for example, 
coronary infarct) are also considered cell therapy, though they do not involve cell 
transplantation.  
 
The first cell therapy in modern medical history was the intravenous transfusion of whole 
blood (rather than required cellular components, as is currently used) from a donor to a 
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recipient. This development became possible because of the identification of human blood 
groups by Carl Landsteiner in 1900, and during the First World War, blood transfusion 
became a consolidated medical practice necessary to restore blood volume after an acute 
haemorrhage (Figure 2).14-22 The next step in cell therapy came with bone marrow 
transplantation (BMT), again historically linked to a world war, when civilians were exposed 
to potentially lethal doses of radiation from atomic bombs, and to subsequent use of nuclear 
radiation. The irradiation-induced damage to bone marrow ranged from aplasia to cancer. 
After many repeated attempts over a period of years, intravenous delivery of whole bone 
marrow finally resulted in transfer of long-term self-renewing stem cells from donor to 
patient with consequent reconstitution of all of the damaged blood cell types, and permanent 
therapeutic effects. 23  
 
Both blood and BMT require immunological matching of host and donor. Additionally, for 
BMT, immune suppression is required unless the donor and recipient are immunologically 
identical (i.e. monozygotic twins, fully matched for both major and minor histocompatibility 
antigens). 
Mobilization of stem cells in the donor’s blood and the use of HLA-matched hematopoietic 
stem cells (HSC) from cord blood - stored in “ad hoc” banks - have further improved the 
simplicity and efficacy of BMT.24, 25  
As well as donor-recipient blood transfusions, autologous transfusions can be made, for 
example, where stored blood from a patient is used for his/her own transfusions required 
after undergoing major surgery.  
 
Similarly, autologous BMT can be used both in malignancies, where ‘disease-free’ bone 
marrow is preserved before the massive myeloid ablation that occurs after radiotherapy. 
More recently, bone marrow stem cells can also be collected and genetically corrected (via ex 
vivo gene therapy – see below) and, for later re-infusion into a patient. Recently this 
procedure has been successfully applied not only to haematological diseases (for example, in 
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congenital immune deficiencies) but also to degenerative disease of the brain as detailed 
below.26-28 
 
Autologous cell therapy has also been used in clinics for large burns to the skin and to repair 
the cornea as shown in Figure 3.29-31 This was made possible by the seminal discovery that 
stem cells from the epithelia can be clonally expanded in culture on a 3T3-J2 feeder layer 
where long term,32 self -renewing “holoclones” will appear. Indeed, epithelial stem cells 
generate large sheets that can be transplanted on the same patient to cover the surface 
previously burned. This treatment results in a long lasting, life-saving persistence of almost 
normal epidermis, though no appendages can be generated.33 In the case of the cornea, 
transplantation from donors resulted in a high failure rate but autologous cell transplants 
resulted in stable success rates of 70% and above. For this procedure, two interventions are 
necessary: one to biopsy the limbus (the border between cornea and conjunctiva where stem 
cells reside) and expand the cells in vitro; another to remove the scar and simultaneously 
transplant the in vitro generated new cornea. This therapy recently became the first cell 
therapy product to receive market authorization in Europe.34  
 
With the exception of blood and bone marrow, all other forms of cell therapy require donor 
cells to multiply in culture in order to acquire the large quantity of cells necessary for 
transplantation. Though commonly used in clinics today, cell culture exposes cells to 
potential damage, such as oxidative and mechanical stress, possibly resulting in mutations 
and chromosome abnormalities, senescence and infection.35-37 As explained below, cell 
therapy for the hematopoietic system and epithelia have seen a far higher percentage of 
clinical success, but new cell types have already entered the clinical arena. 
 
Embryonic and induced pluripotent stem cells: the future? 
Up until now, almost all cell therapy clinical trials have been conducted with post-natal 
stem/progenitor cells (including cord blood), isolated from patient or donor tissue. However, 
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in future, an increasing number of trials will be carried out with 
differentiating/differentiated cells or tissues derived from embryonic or reprogrammed 
(‘induced pluripotent’) stem cells (known as ESC and iPSC, respectively). ESC were originally 
isolated from the inner cell mass of mouse blastocysts, and adapted to proliferate indefinitely 
in culture while maintaining pluripotency (the ability to generate many of the cell types of 
our body). Mouse ESC were identified and characterised in the early nineteen-eighties while 
human ESC were derived only in 1998.38, 39 ESC opened a strong clinical opportunity, 
especially for diseases affecting tissues where adult stem/progenitor cells have not been 
clearly identified or are inaccessible and/or difficult to expand in culture.  However, 
although ESC show the unprecedented potential to differentiate into virtually all our tissues, 
they also presented two key problems. Because ESC are derived from an embryo, they are 
heterologous cells with respect to patient and thus may undergo immune rejection. Secondly, 
it is still difficult to induce differentiation into a desired cell type with 100% efficiency. This 
means that, after differentiation, they may still remain a small fraction of undifferentiated 
cells that continue to proliferate, and may form tumours. Known as teratomas, these consist 
of disorganised but partly differentiated tissues - such as bone, heart, or skin. Moreover, as 
for any type of cell therapy, functional integration into the host tissue will remain a 
consequential, and major issue. 
Because human ESC are derived from human embryos, they have stimulated ethical 
controversy,40 which, taken together with the scientific problems mentioned above, has 
delayed clinical translation of ESC research. 
 
 
A more recent, ground breaking development was the demonstration by Shinya Yamanaka 
that it is possible to re-programme an adult somatic cell to an “embryonic-like” state via the 
transfer of a limited number of genes into these cells.41 This innovation led to the creation of 
‘induced Pluripotent Stem cells (iPSC), which behave in a very similar manner to ESC, but 
with the advantage of being derived from a patient’s own tissues, therefore allowing 
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autologous transplantation as well as creation of mature cell types with specific genetic 
defects (Figure 4).42 Although iPSC do not negate the risk of generating tumours, their 
development has most likely solved the immunological issues. Nonetheless, the idea of a 
heterologous use for iPSC is being developed. This opens the possibility of having banks 
(possibly HLA-specific) that would alleviate the logistics of procurement and reduce costs.43  
In addition, iPSC can be generated from patients with specific mutations, the effects and 
eventual genetic correction of which can now be studied in vitro. This is especially important 
for cells like neurons that are otherwise impossible to study in vitro, given the difficulty of 
obtaining biopsies from the patient.44 
Yamanaka’s remarkable discovery of iPSC was based on previous demonstrations that adult 
nuclei in frogs and in sheep (the famous Dolly) can give rise to a complete animal if 
reprogrammed upon transplantation inside an enucleated oocyte.17  
 
At the time of writing, there are fewer than ten trials being run or recruiting which use ESC. 
These trials focus mainly on degenerative diseases of the retina, considered an immune-
privileged organ. Currently, while there is much pre-clinical research utilizing iPSC, there 
has only been one clinical trial involving transplantation in patients, which started and was 
halted in Japan due to problems concerning the genetic stability of the cell lines used, and 
the need to meet new regulatory legislation.45 However many other iPSC clinical trials are 
being planned, such as the reconfigured clinical trial in Japan to transplant retinal 
progenitors produced from third party iPSC.46 Overall, the situation is not surprising given 
than less than ten years have elapsed since their discovery, even if the ethical issues in this 
case are different.47   
Finally, many recent reports have shown that organ-specific cells could be generated from 
different somatic cells, thus directly bypassing potential (e.g. oncogenic) risks associated 
with pluripotency. Many differentiated cell types (e.g. cardiac, endothelial and liver cells) 
have been directly obtained from a variety of differentiated cells, using specific transcription 
factors, through a process called trans-differentiation.48, 49 As this involves going from one 
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somatic specialized cell to a different type without transiting through an “embryonic” stage, 
it may be safer for patients, and ultimately easier to translate into clinical treatments. 
However, the very preliminary evidence reported so far needs confirmation and robust 
evidence to show that the “converted” cell is functionally fully equivalent to a healthy, 
resident cell of a given tissue. 
 
Gene therapy: general concepts 
Gene therapy aims to correct a genetic defect in a given cell type, to restore function, or to 
provide (a) novel function(s). As for cell therapy, this is a broad definition. Gene therapy was 
designed in the early nineteen-nineties as a strategy to provide cells of affected tissues or 
organs with a ‘normal’ (wild-type) copy of the coding regions (cDNA) of the gene whose 
mutation had caused the disease. It was quickly understood that it is also possible to provide 
cells with a novel function for a specific goal (e.g. express antigens that enhance 
immunogenicity of cancer cells, or provide lymphocytes with mechanisms to more efficiently 
kill tumour cells). Although this work on cancer and related clinical trials are representative 
of the majority of current gene therapy experimental interventions, they are not regenerative 
medicine in the strictest sense and will, therefore, not be discussed in further detail. More 
recently, two possibilities have offered alternative options for correcting a gene defect in situ. 
These are genome editing (for recent reviews see: 50-55) and correcting the mutated transcript 
(exon skipping using antisense oligomers (AOs) or read through a premature termination 
codon or other small molecule-mediated modification of splicing).56-59 These strategies have 
many features in common with conventional drug therapy, being based on either removal 
from the mature transcript of an exon harbouring a mutation, modification of splicing to 
induce exon inclusion, administration of drugs to induce a desired modification of splicing, 
or partial read through of nonsense mutations60, 61 (allowing the production of a full length 
protein despite a premature stop codon). Because of these features, these compounds are 
rapidly progressing, particularly in the fields of Duchenne Muscular Dystrophy (DMD) and 
Spinal Muscular Atrophy (SMA). 
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Classically, gene therapy is divided in two main categories: in vivo - where genes (or their 
products) are introduced directly into a patient’s cells; and ex vivo, in which a patient’s cells 
are grown in culture, genetically modified and then re-introduced into the body (Figure 1). 
The latter strategy is considered a form of cell therapy, which is an illustration of the 
significant overlaps that exist between cell and gene therapy. This is also reflected in the 
shared space both areas co-habit in scientific journals and conferences. 
 
Since the early days of its development, it was apparent that the major hurdle for gene 
therapy would be the delivery of genes into target cells. Genes (or more commonly, their 
cDNA) are very large, highly hydrophilic and electrically charged molecules which by 
themselves do not cross the cell plasma membrane. The use of vectors to carry molecules 
into cells offered a solution to this problem. Viral vectors exploit the ability of viruses to 
enter our cells. Until now, they have been by far the most commonly used, though they are 
not devoid of problems, as described below. Non-viral vectors (such as liposomes) have also 
been tested and long been implemented, but have consistently proved less effective. A new 
generation of nanoparticles now show promise of becoming both efficacious and safe vectors, 
though these are currently predominantly in the pre-clinical phase, with a few trials having 
already begun.62, 63  
 
A viral vector is a virus that has been modified to carry therapeutic cDNA rather than some 
of its own genes (e.g. the disease-causing ones), while maintaining genes encoding for its 
capsid and envelope. Of the many viruses initially tested, the ones currently in use in 
patients are Adeno virus (AV) and Adeno-associated virus (AAV) as non-integrating vectors; 
as well as retroviral vectors (both lentiviral, LV and retroviral, RV) that stably integrate into 
the host cell genome. AV and AAV are predominantly used in vivo in patients.64-66 Retroviral 
vectors are mainly employed in ex vivo gene therapy. While AV vectors accommodate large 
cDNAs, they are highly immunogenic. For this reason they are predominantly used in cancer 
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gene therapy where immunogenicity will enhance the host immune response – something to 
be avoided in the long term correction of genetic defects. In this case AAV are the vectors of 
choice. They are far less immunogenic, and are maintained over a long period of time 
(measurable in months) in non-dividing cells such as skeletal muscle. Since they are 
unavoidably lost from rapidly dividing cells, they are not usually used for hematopoietic and 
epithelial tissues. In addition, they are small and accommodate only small cDNAs (up to 4-5 
kb).  RV and LV, predominantly used for ex vivo gene therapy, also have limits in the size of 
cDNA they can accommodate (up to approximately 5-6 kb). Importantly, they integrate into 
the host cell genome, which ensures prolonged expression of the therapeutic gene, although 
this is accompanied by the risk of insertional mutagenesis, discussed below.67, 68  
 
 
 
Results and challenges of cell and gene therapy 
Cell therapy has produced clinically extraordinary results, having saved hundreds of 
thousands of lives – especially those affected by congenital or acquired diseases of the 
hematopoietic tissue.27, 69-72 This is most likely because there is the option of ablating 
diseased host tissue: bone marrow can be destroyed to various extents by radiation or 
cytotoxic agents, while skin or other epithelia can be surgically removed. These procedures 
create ‘space’ for donor cells (either allogeneic or autologous) and favour their engraftment, 
since they do not have to compete with resident diseased cells. Moreover, blood is a fluid, 
and epithelia are 2D tissues, structurally less complex than organs such as the brain, heart, 
and skeletal muscles, where massive ablation of diseased tissue is clearly impossible. This 
results in much lower donor cell engraftment and consequently, in reduced therapeutic 
efficacy.73, 74 Furthermore, at later stages of degenerative diseases, resident cells have already 
died, and have been replaced by a thick, avascular fibrotic tissue, which makes engraftment 
of donor cells virtually impossible. Because of this, many current experimental strategies 
additionally aim to reduce fibrosis and enhance angiogenesis. A general consensus is 
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emerging that all these therapies, once proved safe, should be tested as soon as possible, 
ideally at diagnosis, before the onset of fibrosis.75 
To date, congenital immune deficiencies represent the major success for gene therapy. 76-82 
With the exception of one major problem, described below, they allowed long-term 
reconstitution of the immune system in children who were otherwise destined to succumb to 
infections.  A scheme of the experimental strategy, based upon auto-transplantation of 
autologous, genetically corrected CD34+ hematopoietic stem cells, is shown in Figure 5.83 
The same strategy was subsequently applied to β-thalassemia,84 and more recently to X-
linked adrenoleukodystrophy,85 a demyelinating disease caused by a deficiency in the ALD 
protein, (an adenosine triphosphate-binding cassette transporter) and to metachromatic 
leukodystrophy,28, 86, a lysosomal storage disease, in which autologous, genetically corrected 
CD34+ cells were transplanted, generating microglia that overproduced and released a large 
amount of the missing enzyme (aryl-sulphatase). The enzyme released was also taken up 
from the extra-cellular space by neighbouring neurons, resulting in molecular and clinical 
correction of the disease. Another example of cell-mediated, ex vivo gene therapy is 
represented by junctional epidermolysis bullosa,87 where the cDNA for Laminin 5 was 
transferred into the patient’s epidermal stem cells with a retroviral vector. The corrected 
epidermal sheets were transplanted on the legs using the same procedure first developed by 
Howard Green, where, though devoid of appendices, they reconstituted functional 
epidermis.21  
Through in vivo gene therapy, Leber's Congenital Amaurosis, a rare inherited eye disease, 
was successfully treated with direct sub-retinal injection of AAV expressing the cDNA of the 
RPE65 gene (Retinal pigment epithelium-specific 65 kDa protein).88-90   
On the other hand, there are many examples of cell therapies which had limited, variable or 
transient efficacy. In the early nineteen-nineties, myoblast transplantation in Duchenne 
Muscular Dystrophy proved safe but not efficacious. This was due to very poor engraftment, 
with most cells dying immediately after transplantation and the surviving cells unable to 
migrate from the site of injection, so that the number of dystrophin-expressing cells was far 
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too low to elicit any functional effect. 91 Almost contemporary with this, the transplant of 
foetal dopaminergic neurons into Parkinson’s patients resulted in variable efficacy of 
different durations (mainly due to the paucity and heterogeneity of donor tissue that made 
standardization difficult).92 Though long-term functional improvement was observed in 
some patients, too few patients could be treated. The field is eagerly awaiting ESC or iPSC-
derived dopaminergic (autologous) neuroblasts which will be available in unlimited 
numbers.93 It is important to note that Parkinson’s may be privileged among 
neurodegenerative disorders as the tissue damage is restricted to a specific anatomical 
location (substantia nigra) – in comparison with multiple sclerosis or amyotrophic lateral 
sclerosis which have a widespread effect on far less accessible regions of the nervous system. 
The difficulty of targeting the nervous system has been, together with “extreme financial 
pressure”, a reason for the recent announced closure of StemCells Inc. after the failure of a 
Phase II trial.94  
 
In the last twenty years, transplantation of different cell types in the infarcted heart has 
elicited generally very modest or no therapeutic effects,95 and even seen the death of a few 
patients. This was due to uncontrollable fibrillation when skeletal myoblasts were 
transplanted, generating another excitable tissue, electrically uncoupled to resident 
myocardium.96 Even if successful transplantation of cardiac stem-progenitor cells or in vivo 
production of new cardiomyocytes was achieved (e.g. by trans-differentiation of non-cardiac 
cells), newly generated cells would most likely be the size and the functional maturity of an 
embryonic, newly differentiated cardiomyocte, far smaller than an adult one, and thus 
hampered in achieving correct electrical coupling.  
 
Islet transplantation is an established (though non-optimal) therapy in diabetes, mid-way 
between cell and organ transplantation. It is still in need of significant development,97 both 
due to the need for constant immune suppression, and because long term correction of 
glycaemia is achieved only in a minority of patients. A very large amount of preclinical work 
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is ongoing and many trials have started or are ready to start for other diseases, for example 
with embryonic stem cell-derived retina progenitors for macular degeneration or other 
retinal diseases. See98 for a recent review. 
 
While the primary goal of cell transplantation is replacement of lost or damaged tissue, it has 
recently been reported that intravenously injected cells appear to exert beneficial effects even 
if they do not replace lost tissue to any significant extent.99 This is ascribed to the purported 
production of growth factors or other bioactive molecules that ameliorate the survival of the 
residual tissue, for example by enhancing angiogenesis, and, therefore, increasing the supply 
of oxygen to the affected area. However, this concept of a “cell drugstore” is highly 
controversial.100 5 Many clinical trials have been conducted based on this concept, but results 
are still inconclusive and more rigorous evidence of real “engraftment” and type of function 
should be provided to resolve this controversy.  
  
 
With respect to gene therapy, initial excitement about this new frontier of medicine was 
dampened by severe problems, including a few deaths that delayed clinical success by almost 
twenty years, so that is only now finally becoming revived for many diseases. The stumbling 
blocks were represented mainly by the then poorly understood variability in immunogenicity 
and toxicity of different vectors across species, meaning that pre-clinical work was not 
always fully predictive of outcome in patients. In addition, the erroneous initial belief that a 
good vector would work equally well in a variety of tissues affected by different diseases led 
to a number of strategic errors that time and experience eventually corrected. For example, 
AAV- producing Factor IX (FIX) virtually cured Haemophilia B in pre-clinical work on mice 
and dogs but turned out to be immunogenic in patients, leading to destruction of corrected 
liver cells.101 This problem was partially solved by changing the serotype of AAV used to 
transduce human liver cells and allowing therapeutic levels of FIX to be expressed long 
term.102, 103 Administration of a relatively high dose of an AV expressing ornithine 
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transcarbamylase, well tolerated in primates and in the first patient treated, led to a systemic 
inflammation and multi-organ failure in a second patient who died after four days.104 This 
tragic event put a stop to the trial and stimulated new research aimed at delivering safer 
treatments in the future. Years later, five children participating in trials for a Severe 
Combined Immune Deficiency (SCID) developed a T cell proliferative disease 105, 106 which 
led to the death of one of them, despite the recovery of all the others from the otherwise 
invariably lethal disease. The event was due to activation of neighbouring proto-oncogenes 
by powerful enhancer elements in the vector and has subsequently been observed in other 
protocols using early generation retroviral vectors. Since then, more sophisticated 
methodologies have been developed to reduce the risk of insertion near gene regulatory 
regions (by changing from retroviral to lentiviral backbones); and to limit the potential of 
transgene regulatory sequences to trans-activate target cell genes. These changes are unlikely 
to abolish the risk of this insertional mutagenesis completely, but on-going trials suggest that 
the risk is very significantly reduced.107, 108  
 
The examples reported above should not mask the fact that nowadays several dozen children 
born with incurable diseases are well, at home, and living a normal life thanks to the success 
of cell and gene therapy, without which they would not still be alive. Never in the history of 
medicine has progress occurred without a toll to pay – sadly, often through the lives of the 
first patients undergoing experimental therapy. While risk should be reduced to a minimum, 
the only way to completely eliminate risk is to stop new experimental protocols and with it, 
medical progress; in this context careful evaluation of the risk/benefit balance becomes 
crucial. Moreover, it would be unethical to use these therapies unless the disease was severe 
and no valid therapeutic option was available. For example BMT with autologous, genetically 
corrected cells was initially only considered suitable for patients affected by congenital 
immune-deficiencies who did not have an HLA-matched donor. Now gene therapy appears 
to be at least as efficacious and safe as standard BMT, and could become the therapy of 
choice for some conditions. 
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Another important consideration relates not only to the severity but also to the duration of 
the disease. Metachromatic Leukodystrophy and Duchenne Muscular Dystrophy are both 
lethal diseases but the first (in its most severe form) leads to death within the first years of 
life; while, thanks to better cardiac and respiratory assistance, the second now allows 
patients to survive to around age forty and sometimes more. The risk of a new therapy is well 
justified in Metachromatic Leukodystrophy patients who arguably have very few years 
ahead; but much less so in the second group, who may live for decades, and have time to wait 
for a less risky therapy. There is a more extensive discussion of this topic in the section on 
Ethics and Regulation below. 
 
 
Modification of splicing: Antisense oligonucleotides and small molecules 
 
Targeting mutant RNA in Duchenne muscular dystrophy using antisense oligonucleotides 
(AONs) has been an exciting development of recent years. The use of splice switching AONs 
to induce restoration of the reading frame has been mostly developed for Duchenne 
Muscular Dystrophy. An exciting recent development is also that of the utilisation of AONs 
to induce exon retention, with Severe type I spinal muscular atrophy (SMA) being an ideal 
condition for this.  
 
SMA is a motor neuron disease, affecting infants, who typically die by the age of 2 years. 
These infants never acquire the ability to sit. In a recent phase I clinical trial involving 
patients with SMA, systemic delivery of AAV9 were, on the whole, well tolerated with the 
exception of a transient transaminitis. This is a relatively common issue in AAV gene therapy 
trials, and led to a dose response in terms of intervals free from the development of severe 
respiratory insufficiency. In a proportion of the children receiving the higher dose, AAV9 
gene therapy led to remarkable acquisition of new milestones including sitting, standing and 
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walking (Jerry Mendell, late breaking presentation, World Muscle Society 2016, Granada). 
Regarding AON therapies, as these compounds are not capable of crossing the blood brain 
barrier, this involved repeated intrathecal administration in SMA patients in order to 
maintain adequate SMN (Survival of Motor Neuron) protein level.  
 
In the last few years, nusinersen, one such AON, has been studied as part of a comprehensive 
program of open label and randomised placebo controlled studies in SMA type 1 and for the 
milder variants SMA types 2 and 3. Published data on a phase 1 study in 28 SMA patients 
demonstrated safety of 4 ascending doses. The pharmacokinetics were indicative of a 
prolonged cerebro-spinal fluid drug half-life (4–6 months), and clinical outcome data was 
encouraging.109  Data from a more recent phase 2 study in infants with type 1 SMA indicated 
safety and tolerability of nusinersen, with both respiratory and motor milestones 
demonstrating significant divergence from natural history of the condition. Not only was the 
ventilation-free survival of treated infants significantly divergent from the natural history of 
the disease, but the majority of treated infants improved their functional scores and acquired 
independent sitting - and in a few instances, also standing. Very recently, the top line results 
of a randomised, placebo controlled study in type 1 SMA  (Endear study) were announced by 
the Sponsors Biogen and Ionis. As the prespecified interim analysis demonstrated a 
significant improvement in the proportion of nusinersen-treated motor milestones 
responders vs sham procedure control, the placebo controlled part of the study was 
interrupted and all patients are currently transitioning to an open label extension. 
 
In DMD, AONs targeting mostly exonic splicing enhancers can induce exon skipping and 
restoration of the reading frame in boys with eligible out-of-frame deletions. This strategy to 
induce deleted but in-frame molecules mimics what happens naturally in the much milder 
Becker muscular dystrophy (BMD) condition. Different chemistries are currently in clinical 
trials in the DMD field, the 2’OMethyl (2’OMe) backbone, and the morpholino (PMO) 
backbone, developed by two different industrial partners (Prosensa/Biomarin and Sarepta 
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Therapeutics respectively). Since 2009, a number of phase I and phase II studies have been 
published, dealing with DMD patients who can benefit from exon 51 skipping, as this is 
potentially beneficial for the largest number of deleted DMD patients (~ 13%). Targeting 
another nine exons would achieve correction in approximately 70% of DMD boys carrying 
deletions. Indeed, phase I studies targeting exon 45 and 53 are now well underway. The 
outcome of several open-label studies and of two placebo-controlled studies of both 
chemistries targeting exon 51 were encouraging. They demonstrated the production of 
dystrophin in muscle biopsies of the children studied, although with differences in efficiency 
of the 2 chemistries. Encouraging clinical benefit was reported once treatment was 
prolonged for several years, with statistically significant and clinically meaningful 
stabilization of functional abilities in treated children (as measured by the six minute 
walking test) 45-47. However, the outcome of a phase III study using a 2’OMe AON targeting 
exon 51 was inconclusive. An important contributory factor for this disappointing result 
could be ascribed both to the relatively short duration of the study (48 weeks), and, more 
importantly, to the more advanced clinical features of the boys recruited into this Phase III 
study, compared to previous trials. Because in DMD there is a progressive loss of muscle 
mass (and hence less tissue) to be ‘rescued’ by the AON therapy, the stage of the disease in 
children recruited is of paramount importance, as is the duration of the clinical trial. This 
makes it possible to observe divergences in the clinical course between treated children and 
the placebo group. The 2’OMe AONs exon 51 safety profile was consistent that of this class of 
compounds (skin reactions following repeated sub-cutaneous administration; reversible 
renal toxicity, occasional trombocytopenia) requiring careful clinical monitoring. In view of 
the unfavourable risk/benefit profile, and following the negative evaluation of this 
compound for market authorisation by both FDA and EMA, the sponsor (Biogen) has 
interrupted the development of 2’OMe compounds for DMD.110 
A different outcome was seen in the recent FDA accelerated approval for the morpholino 
AON, developed by Sarepta to skip exon 51 (Exondys). This was based on the clinical 
trajectories of a group of children treated for more than 4 years compared to carefully 
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matched untreated children. An excellent safety profile of the PMO AON; and an 
unequivocal increase in dystrophin expression was demonstrated in the study, and in 
another ongoing phase III study, currently underway. The FDA decision to grant market 
authorisation of this Sarepta AON compound has been criticised by some, mostly due to the 
small number of children treated and the low levels of dystrophin produced. 111  
While novel larger studies targeting exons 51 and others are now underway, considerable 
research has also been devoted to future generation AONs with improved efficiency in 
targeting skeletal and cardiac muscles. Considerable improvement in efficacy and 
biodistribution has recently been achieved with the use of peptide-conjugated morpholino 
AONs and of tricyclos DNA. The safety profile of these more novel AONs will now need to be 
assessed to determine whether these molecules are ready to enter the clinic as they stand. At 
the same time, novel strategies (e.g. TALEN, Zinc Finger and CRISPR-Cas9 nucleases) for 
permanently editing the genome (rather than continuously repairing the pre-mRNA) appear 
promising, but still face the common problem of delivery, especially into large tissues such as 
human muscle. 
 
Tissue Engineering 
 
Tissue engineering combines the fields of cell biology and material science. Its major goal is 
the generation of tissues and organs that might be used for regeneration, replacement or 
reconstruction, particularly in areas of unmet clinical need. The rapid development of the 
field has been driven by the plight of patients requiring healthy tissues and organs, but for 
whom conventional reconstruction is unsuitable; or where allotransplantation is limited by 
the availability of appropriate grafts of human origin, the need for immunosuppression, or 
technical considerations. Every day, around 13 people in the UK alone receive organ 
transplants. At the same time, around 4 people die or become too sick to receive a transplant 
while on the waiting list. The immunosuppression of those lucky enough to receive a graft 
also incurs considerable risks of multiple infections and an increased risk of cancer, and 
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reduces life expectancy (NHS Blood and Transplant Annual Review 2012-13).112 The 
development of safe and effective tissue-engineered alternatives would reduce mortality both 
by decreasing the number of patients on transplant waiting lists, and by eliminating the 
excess morbidity and mortality associated with immunosuppression. 
 
The term “tissue engineering” was popularized by Langer and Vacanti,113 and alludes to the 
combination of biomaterials, cells, and biologically active factors used to effect tissue 
formation. The process can involve de novo growth in tissue culture (in vitro, ex vivo), or 
induction of tissue regeneration in vivo at sites or under conditions where it otherwise would 
not occur. 
 
Biomaterials provide the three-dimensional structure supporting cell engraftment and tissue 
growth. Ideally, they should not lead to an adverse immunological response from the host, 
should biodegrade in a suitable time period that permits sufficient cellular growth (whilst 
not producing harmful degradation products); and possess appropriate biomechanical 
properties compatible with their intended physiological function. To date, such materials 
have been divided into naturally derived materials, synthetic materials and natural, a-
cellular (‘biologic’) scaffolds. Materials composed of naturally occurring macromolecules, in 
particular those that formulate the extracellular matrix (ECM) – such as collagen – have 
been tested for tissue engineering purposes, but struggle to mimic the complexity of the ECM 
composition in vivo.  
 
Synthetic materials have been considered, following their successful use in other areas of 
medicine. The polyester family of poly(L)-lactic acid (PLA), poly-glycolic acid (PGA) and 
poly-lactic-co-glycolic acid (PLGA) has long been used in sutures and orthopaedic fixatives, 
and has been widely applied to produce scaffolds. Degradation of these scaffolds occurs 
through hydrolysis, and the degradation rate can be manipulated by altering material 
properties such as crystallinity, molecular weight and porosity. The existing wide clinical 
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application of polyesters supports their biocompatibility, although some studies suggest 
there can be problems due to their propensity to disintegrate into small particles, or result in 
toxicity and inflammation associated with acidic degradation. When large volumes of tissue 
are engineered, vascular supply becomes a critical limiting factor with synthetic materials. 
Angiogenesis and cell migration and attachment into such materials have been shown to vary 
with properties such as porosity and surface moieties.  
 
For many clinical tissue engineering purposes, it is possible that the rich innate molecular 
and microarchitecture of extracellular matrix scaffolds may be superior to both simple 
naturally occurring and synthetic materials, at least in the short term. Such natural a-cellular 
matrices are derived from human or animal organs or tissues which have been treated to 
remove cells and other adversely immunogenic material, resulting in natural scaffolds that 
maintain their original architecture and at least 200 different biologically active (and 
potentially useful) molecules.  
 
Organ and tissue decellularisation is believed to represent a potentially rich source of 
scaffolds for transplantation. For this reason, advancement towards the engineering of 
complex functional organs has attracted considerable public interest and funding 
internationally. If this strategy is successful, the approximate 40% of organs from human 
donors which (for medical or technical reasons) are not used for transplantation every year 
could be converted into valuable therapies. Additionally, since the majority of ECM proteins 
are highly conserved, decellularised organs from animals and could also be engineered, and 
‘humanised’ by seeding with human cells. In fact, for decades, porcine and bovine tissue has 
already been used to treat patients, for example in heart valve replacements and tissue fillers. 
Antigens that have prevented the use of xenogenic organs, such as the highly pro-
inflammatory galactosyl-(1,3)galactose (Gal) which causes hyper-acute rejection are likely to 
be eliminated by the decellularisation process, and if not, genetically modified pigs that lack 
the Gal epitope are now available.   
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Internationally, a number of groups have used somatic cells for tissue engineering relatively 
simple organs serving as bodily conduits such as the trachea,114 urethra 115 and bladder,116 
with some encouraging results in short case series and early phase clinical trials. As well as 
mostly helping the patients receiving them, these early attempts at clinical translation have 
also served to highlight critical barriers to progress, such as vascularisation, biomechanical 
properties and contractility. Overcoming these problems is essential before the definitive, 
larger scale clinical trials and commercialisation can be completed and thereby introduce 
organ tissue engineering as a routine therapeutic option. As opposed to surgical meshes, 
which can be revascularised adequately after implantation, the presence of cells within these 
constructs requires an immediate blood supply to maintain cell survival due to the thickness 
of the tissue and corresponding diffusion distance. Loss of biomechanical properties has also 
caused problems for patients receiving both tissue engineered tracheas and bladders.117, 118 
 
One alternative solution would be the use of three-dimensional (3D) printing of 
biocompatible materials, cells and supporting components in complex 3D functional living 
tissues, 119 or 3D bioprinting of tissues and organs. While 3D bioprinting has already been 
used clinically for the generation and transplantation of acellular tracheal splints,119 more 
complex tissues containing cells such as multilayered skin, bone, vascular grafts, heart tissue 
and cartilaginous structures have been investigated both in vitro and in vivo. In the future, 
appropriately ‘decorated’ cell-free polymers might be used for these engineered organs, with 
the expectation of host tissue and vascular ingrowth. Presently, however, tissue engineering 
solutions largely rely on the seeding of large numbers of cells, either with the ability to 
undergo multiple functional differentiation (stem or progenitor cells) or with mature cells 
(Table 1).115, 120-123 As for cell therapy, ESC and iPSC may become a valuable resource in tissue 
engineering as well as directly converted adult cells, as discussed above. 
Despite the promise of a potential replacement for conventional organ allotransplantation, 
early clinical experiences have highlighted major technical and biological hurdles, scientific 
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and clinical controversy,124 and commercial problems. Among these, the widely reported 
discharge of a distinguished surgeon from the Karolinska Institute and resignation of two 
Nobel committee members drew negative attention on the field of artificial organ 
transplantation. Such cases of individual misconduct, however, could equally have happened 
in any field of experimental medicine, with detrimental effect.125 Even so, if the exciting 
potential of tissue engineering is to be fully realised, all of the challenges described above will 
need to be overcome.   
Current research and practice of cell and gene therapy and tissue engineering would benefit 
from the enhancement and support of a) “clinician scientists”,126 both in medicine and in 
surgery, who are also cell, molecular or material biologists; b) academic Good Manufacturing 
Practice (GMP) facilities to absorb and reduce costs; and c) a new generation of regulators 
who fully understand and, ideally, have been working in regenerative medicine (see 
Recommendation “Better science”).  
  
 
Small trials, difficult statistics, difficult regulation and data reproducibility. 
 
With few exceptions (e.g. cell transplantation for heart infarct) the clinical work described 
above has been conducted on small cohorts of patients who, for many diseases, show 
dramatically different progression and phenotypic heterogeneity, independent of the type of 
disease. This is due to both the rarity of these diseases and to safety reasons. Therefore, the 
costs of developing treatments are very high and the risk to which the patients will be 
exposed, relatively unknown. When risk is difficult to assess and quantify, it makes 
regulation for safety concerns problematic. Efficacy also becomes challenging to assess 
because reliable outcome measures remain difficult to define. The net result of these factors 
is a situation in which – for cell therapy, gene therapy and tissue engineering – there is a 
dearth of the type of data that have become expected for conventional pharmaceutical 
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products before market authorization is given, and even before research investment 
decisions are made. 
 
This creates a vastly different scenario from classic drug trials, which use large populations 
of randomized patients. In a very small number of cases (e.g. immune congenital 
deficiencies) the clinical outcome is so striking (disease-free survival versus death) that 
statistics are not needed;28, 108, 114 market authorization is relatively simple to obtain, and data 
do not need careful meta-analysis, other than patient follow up. Glybera represents another 
interesting case, particularly in relation to the regulatory landscape.127 The product, an AAV 
producing protein phospholipase is delivered through an intra-muscular injection in an 
extremely rare population of patients – who, missing this enzyme, undergo repeated attacks 
of acute pancreatitis. Market authorization was initially denied because of insufficient 
statistical evidence (one patient had another attack of acute pancreatitis after treatment), but 
this was later reconsidered. Conditional authorisation was granted using the trend, rather 
than statistical validity, as an indicator.  But cases like immune congenital deficiencies, and, 
to a lesser extent, Glybera, are exceptions. The rule is that often the effect is modest or very 
modest. Nevertheless, it suggests that further protocol implementation may, in a stepwise 
progression, lead towards clear efficacy and improvement in patient health and quality of 
life. However, since the cost of these therapies is very high, the first challenge is to raise 
money for a trial that cannot promise, at best, more than a minimal effect.  
 
Funding agencies may be reluctant to finance these projects, but are also aware that, in not 
doing so, the particular strategy in question is killed, together with the possibility that, in 
time, it may have brought some real benefit. A solid, reliable and reproducible pre-clinical 
study in animal models (when available), in iPSC derived patients’ cells, or organoids (3D 
cultures that to different extents mimic miniaturised developing organs)128 will increase the 
chance of convincing investigators and, subsequently, funding bodies that a specific 
therapeutic strategy may yield a small but tangible effect.114 Nonetheless, funding agencies 
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need to balance allocating their limited budgets between financing research on expensive, 
high-risk, potentially revolutionary regenerative medicine interventions that could only be of 
benefit to small patient populations (at least in the short-term) against other less ground-
breaking projects that may or may not have a larger population impact.  
 
In defining reliable and objective end points that could produce a clear result, whether 
positive or negative, the problems of small cohorts and variability become pronounced: few 
patients will experience a detectable benefit, others will not and some may even see their 
conditions worsen. In the age of personalized medicine, there are theoretical explanations 
for this, but in practical terms, determining the reasons for such variability equates to 
looking for the proverbial needle in a haystack. In such cases, a logical course of action would 
be to do more trials aim to better understand heterogeneity in response.  
 
But, raising additional funds in an environment of such uncertainty is currently a major 
difficulty, despite the increasing funding that certain countries (e.g. UK) allocate to this area 
(see below). Moreover, a few further complicating issues need to be considered. The first is 
that journals and funding agencies naturally privilege both basic and clinical studies that 
show a clear positive result. This creates a real risk of ‘beautification’ of data, for example by 
arbitrarily excluding patients who produce negative results. Big Pharma offers countless 
examples of such practices in the process of bringing a drug to market, in which superior 
efficacy and safety is then claimed over pre-existing drugs. 
 
Such reporting practices go on to affect academics, small companies and large 
pharmaceutical industries for distinct reasons. One solution to the problem is to look to 
reproducibility of data by independent, unbiased investigators. In practice however, this is a 
very difficult (if not impossible) task in early phases: with the difficulties of getting such 
work funded and published, few researchers will spend time and money on confirming 
someone else’s data. It is also important to underline that for more technically demanding 
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methodologies such as cell therapy, lack of the necessary specific expertise may lead to 
failure, simply because the medicinal product obtained when the protocol is reproduced is 
suboptimal. This is especially true in the case where stem cells are extensively expanded in 
culture, where a suboptimal environment may lead to loss of their regenerative features.129-131 
These factors can lead to a mismatch of the quality of the product used by the original 
investigators.  
 
To move from what is currently a ‘catch-22’ situation resulting in wasted time and resources 
– and moreover – one which may lead to public distrust in medical research in this area, a 
suggested partial solution would be a demonstration of willingness from funding bodies and 
leading journals to support confirmatory studies. In this scenario, coherent, reliable and 
concurring data would be publically available before clinical studies move into Phase III.  
 
 
Health economics of regenerative medicine 
 
The cell and gene therapy industry has sharply increased in recent times with dramatic rises 
in levels of investment, clinical efficacy, deals and partnerships, and government support. 
Worldwide, there are over 300 companies focused on cell and/or gene therapy. Many of the 
major big pharma players, including GlaxoSmithKline (London, UK), Novartis (Basel, 
Switzerland), and Pfizer (New York, NY, US) have cell and gene programmes that they are 
actively pursuing, either in-house, or through partnerships with smaller academic or 
industrial pioneers. The large range of indications being targeted varies from diabetes, 
cardiovascular disease and oncology indications (including haematological malignancies and 
solid tumour targets), to eye diseases, skin ulcers and rare genetic diseases. For those 
treatments to be successful, careful navigation of clinical trial pathways is required, as well as 
overcoming remaining scientific, manufacturing, and regulatory hurdles.  
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All regenerative medicine today has benefited from the result of decades of basic research; as 
such, it is essential that funding to the basic sciences is protected (see Recommendation 
“Better science”) within the significant public and third-sector funding being invested in 
regenerative medicine. In 2010, it was estimated that 79% of all UK funding for regenerative 
medicine was for translation science, leaving just a fifth available for research aimed at 
commercialisation.  
 
Still, taken as a whole, over the last 10 years regenerative medicine has also been receiving 
small but increasing investment from the private sector.132 The preponderance of public and 
charitable investment is typical for emerging technologies. As alluded to in the previous 
section, it is also a reflection of the situation that small, low capital private enterprises are 
not optimally suited to R&D and subsequent technology delivery of high-risk, high-cost 
technologies, with long time horizons to benefit and small market sizes. 
 
It is widely accepted by health economists that markets for health and healthcare do not 
typically satisfy criteria that define perfectly competitive, efficient, markets. In addition, 
where such markets or close approximations do exist in healthcare, and function well, they 
may still fail to deliver results that are in line with other desired societal objectives beyond 
efficiency. In particular, many societies choose to sacrifice some degree of efficiency in 
pursuit of other important societal objectives, notably equity. Balancing these two, often 
conflicting priorities, typically leads to government intervention in the market place. In 
many systems, intervention comes in the form of the creation of single payer systems (such 
as the UK NHS) or highly regulated mandatory health insurance schemes (such as in 
Germany or France). The effect of these systems is to counter some of the market power 
enjoyed by many providers of health products and technologies (power that arises, for 
example, through the patent system). These systems also give rise to powerful bodies that 
have authority to determine which therapies are reimbursed through the payment system, 
with obvious potential consequences for regenerative and stem cell therapies. 
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Within this scenario the patent system arguably achieves the objective of encouraging 
innovation through the granting of temporary exclusivity, but its real effectiveness is open to 
debate.  Owing to the length of time taken to secure market authorisation, the patent term 
for a cell therapy product tends to be very short and poorly compensated by the grant of a 
supplementary protection certificate, which can provide no more than five years of patent-
equivalent exclusivity. There is, in consequence, considerable pressure on patentees to 
recover development costs and reward investors within a shorter period of time than would 
be possible for the inventor of a new toaster or even a new small molecule drug.  Perhaps 
unsurprisingly, therefore, the awarding of patents encourages what some regard as socially 
sub-optimal pricing for treatments. The system gives patent owners a temporal monopoly, 
enabling them to levy royalty premiums on commodities in addition to any bare commodity 
profit.  In maximising these benefits, patentees are not driven by the socially optimal level of 
supply, which may be greater. As a result, the gain of treatment accumulates more to the 
patentee in revenue than it does to the population in terms of health gain, at least over the 
short to medium term.  Nevertheless, in the case of cell products, the returns may be so 
unrewarding as to deter investment in the first place. Indeed, where inventions are derived 
from fertilised human eggs, patents are unavailable in Europe anyway. Patenting tends to 
accumulate around processes and equipment (especially important given the dominance of 
in-house, autologous treatments in which no cell product is ever placed on the market). In 
contrast, cells enjoy potentially far longer exclusivity outside the patent system by virtue of 
the clinical data needed to secure an authorisation. Cell products benefit from a potentially 
far longer period of data exclusivity than the eleven years available to orthodox medicines, 
simply because of the impossibility of “biosimilar cells” ever arising: competitors must go 
back to square one and provide their own data to satisfy regulators, at considerable cost. 
 
Market power 
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In the context of regenerative medicine, payers must typically meet a range of objectives 
across whole populations. In many healthcare markets, centralisation of the purchasing 
power in healthcare gives rise to a set of powerful organisations in the form of 
reimbursement authorities. These organisations are tasked with determining what goods and 
services should be provided within the publicly funded healthcare systems to better meet 
societal objectives and to make efficient use of healthcare budgets. In some cases, these 
organisations exert considerable influence on the market for goods, and have the power to 
offset the market power of monopolists. Treatments deemed ineligible for reimbursement 
will have limited opportunities in most markets. From the perspective of reimbursement 
agencies, regenerative medicine may not offer cost-effective forms of therapy using existing 
reimbursement standards.  
Reimbursement agencies frequently consider the cost-effectiveness of a therapy – its value 
for money – as part of the approvals process. Such criteria mean that where costs are high 
and expected benefit to patients is highly uncertain – as is typical a nascent industry such as 
regenerative medicine – reimbursement is less likely. High costs at this stage in an industry’s 
development are almost certainly unavoidable, arising as they do from the costs of research 
and development at the cutting edge of biology and technology, the limited scale of 
manufacturing, and the regulatory burden necessary for bringing novel treatments from the 
lab to patients. From the perspective of the manufacturers, without confidence in 
reimbursement, they bear the risk of developing therapies at a great cost, but finding no 
market in which to sell them. In other areas of medicine that have faced similar challenges of 
high cost and uncertain patient benefit, three arguments are commonly put forward as to 
why reimbursement should cover therapies that are otherwise not cost-effective (see 
Recommendation “Better funding models”).  
 
The first is that reimbursement agencies should consider paying a premium for innovation to 
encourage the development of new therapies. To the extent that products are patented, they 
will have no option: inventors are granted a temporary monopoly through patent protection, 
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and are then free to set a price. If price is determined such that a treatment is at the margin 
of cost-effectiveness then the producer gains all of the benefits of innovation, as any health 
benefit that accrues from the new treatment is offset by health loss elsewhere in the system. 
The health system only gains from an innovation once the patent period has expired and 
other producers can enter the market, typically leading to a drop in prices through 
competition. Others have argued that this is insufficient, as the cost of a new therapy may be 
high in the present but subject to reimbursement costs would be reduced in future through 
further innovation. The argument runs that if current innovation is not rewarded, then 
future innovation may not happen.  
 
By asking health systems to pay for innovation now, manufacturers can shift the burden of 
risks associated with future research and development to the public purse. If future benefits 
from innovation are not realized, then the manufacturer has obtained the premium on the 
original innovation. On the other hand, if benefits are realized, then the manufacturer can 
set the price at the margin of cost-effectiveness and be rewarded – again – for the 
innovation. No doubt, in some cases they may also seek to argue for an additional innovation 
premium. From the health system perspective, allowing additional payment for innovation 
risks paying for benefit twice over, and assuming the risk of developing future therapies. As 
many therapies – particularly in regenerative medicine - are also developed through basic 
science research funded by the public, there is a significant risk that the value of treatment in 
terms of health displaced is not worth the expected lifetime cost.     
  
The second line of argument is that some medical conditions should be considered under 
special rules for rare – or orphan – diseases. Such treatments are known as orphan drugs (or 
treatments). Orphan drug designation may apply if the treatment is being developed for a 
condition in which there are very few patients within a population. In these situations it may 
be unlikely that a manufacturer would invest resources in developing treatments as too few 
patients would require the treatment and the price required to obtain a return on investment 
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would not be acceptable to payers. To address this, government intervention may be 
required in order to induce manufacturers into the market. Such inducements may take the 
form of enhanced patent protections, the creation of a favourable research environment 
through tax breaks or other forms of subsidy, or direct funding of early phase research. 
Although treatments developed for orphan designations (Orphan Medicinal Product Regulation, 
Regulation 847/2000) may not meet cost-effectiveness criteria, they may be approved for 
reimbursement. A reduction in efficiency may be considered an acceptable exchange for 
reasons of equity improvements. Where regenerative medicine products meet the criteria for 
designated orphan treatments, reimbursement may be more likely.   
 
The third argument in favour of paying a premium for treatments is that society in some 
way, (especially affected patients and related patients’ associations) value these treatments 
more highly than other treatments, therefore, they are worthy of reimbursement despite 
being less cost-effective than other treatments when standard decision criteria are applied. 
This approach is exemplified by the end of life care criteria that the UK’s NICE can apply in 
certain cases. This occurs in situations where a treatment is not otherwise considered cost-
effective but may provide some benefits to a select group of patients who are near the end of 
life. In this case the public argument is that society values a certain segment of the 
population as more worthy of treatment than other patients in need, and diverts resources to 
the favoured end of life group. The UK provides a second example of this through the Cancer 
Drugs Fund, a ring-fenced allotment of public financing which enables some patients to 
access otherwise cost-ineffective cancer therapies. The funding cannot be used to provide 
care for those with other conditions, but who also do not have access to cost-ineffective 
therapies. Such approaches may be used to help achieve societal or political objectives that 
are not captured in the cost-effectiveness assessment process. However, increasing evidence 
is emerging that suggests such approaches may be more likely to subvert societal preferences 
and is often in opposition to expert advice on allocating resources. It might be that those in 
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the regenerative medicine field should exercise caution in pursuing such a strategy given the 
risk of backlash.  
 
In some jurisdictions, notably the United States of America, public financing of care is more 
limited and where it does exist (Medicaid, Medicare), it is often not subject to value based 
criteria for determining which goods should be provided. Market conditions are therefore 
more likely to be favourable for therapies early in development where higher costs are not as 
significant a barrier.     
 
Economic barriers to implementing regenerative medicine more widely 
One of the greatest challenges facing regenerative medicine is how to transition from proof 
of concept models in the lab and early phase clinical trials, to production on a scale that will 
drive down costs of treatment. Treatments will have to be developed with standardisation in 
mind where possible. The more bespoke a treatment is required to be, the greater the likely 
cost.  This is because treatments will need to be produced at a smaller scale, increasing 
production costs, and they may need to be accompanied by companion diagnostics to inform 
customisation. The use of automated production techniques and lower skilled staff will most 
likely be necessary to drive this process. Understanding whether and how it will be possible 
to produce at scale will be an important determinant of whether regenerative medicine 
moves from a boutique, expensive cottage industry to mass production that can take 
advantage of economies of scale.  
 
One barrier to scalability is the availability of suitable manufacturing facilities. Again, there 
is significant risk here to manufacturers. Given the early stage of the industry, manufacturers 
may be reluctant to invest in manufacturing capacity – they may not yet know what sort of 
facilities will be required, or on what scale. In the UK, the government and research funding 
bodies have recognised this problem, and money has been made available to further research 
in manufacturing technology and processes. For example, the Engineering and Physical 
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Sciences Research Council have established a Centre for Innovative Manufacturing in 
Regenerative Medicine. The centre aims to foster collaboration between academics, 
clinicians and industry in the development of new ways of bringing regenerative medicines 
to market in cost-effective ways. In the short-term, public funding to support the 
development of manufacturing technologies will continue to be necessary, as governments 
are one of the few institutions capable of bearing the risk of failure. This investment of public 
money, may in the longer term, lead to greater investment from private sector organisations.   
 
However, the emotional impact of devastating and presently incurable diseases may create a 
complex situation, where small companies and short term investors may have their risk 
covered by “payers”, while becoming sole beneficiaries of the eventual profit. Moreover, they 
may exaggerate the potential benefit of a given treatment and lobby to get market 
authorization. Once this is granted (examples of this already exist) they may fix an exorbitant 
price, in which the emotional support of patients is employed to overcome any legitimate 
doubts of the reimbursement authorities.   
 
Considerations for the cost-effectiveness of regenerative medicine  
Cell therapies and regenerative medicine, with their potential to improve the health of 
patients, represent a structural shift in health care by focusing on the underlying causes of 
disease by repairing, replacing, or regenerating damaged cells in the body. As discussed 
above, the potential exists to significantly reduce the burden of disease for some common 
conditions, (e.g., stroke, heart disease, progressive neurological conditions, autoimmune 
diseases and trauma). As well as increasing life expectancy, regenerative medicine therapies 
could greatly improve the health-related quality of life of many patients with chronic 
diseases. Moreover, regenerative medicine could have a major impact on health services, 
significantly reducing demand for health care (See box. 2). However, the potential health 
benefits and cost reductions to the health service must be balanced against the costs of 
regenerative medicine, which are also potentially huge, and which would be borne by the 
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health services. Moreover, so far only a handful of rare diseases have been successfully 
treated. While the cost of developing such therapies will remain to be covered before results 
are known, there is no guarantee that more common, polygenic or acquired disorders may 
also be successfully treated. 
 
While there is reason to believe the potential value for money of regenerative medicine, there 
is at present very little actual evidence. Several studies calculate the current cost of diseases 
that could potentially be eradicated or reduced using regenerative medicine (e.g., heart 
disease, heart failure, diabetes, stroke, end stage renal failure, Parkinson’s disease, spinal 
cord injury) producing figures of many millions of dollars,133-137 but there is no evidence 
related to the proportion of these costs that will be avoided because of regenerative medicine. 
In addition, the potential cost savings are not balanced against the costs of the regenerative 
medicine interventions themselves, which will be substantial.   
 
There are very few formal cost-effectiveness analyses of regenerative medicine interventions 
– the kind of analyses that might be required by bodies such as NICE in England. For 
example, a review of the international NHS Economic Evaluations Database at the Centre for 
Reviews and Dissemination (Crd.york.ac.uk) using the search terms “regenerative medicine” 
OR “tissue engineering” OR “cell therapy” in any field found only eight studies (last checked 
June 2016).  
 
Even if regenerative medicine was cost-effective based on the metrics commonly used by 
organisations such as NICE (e.g., in terms of the incremental cost per quality-adjusted life 
year gained), it is unclear whether health services would have sufficient budgets to be able to 
afford to implement them. Huge benefits might be reaped from regenerative medicine but at 
huge cost, and affordability may limit implementation, even if there is a good chance of cost 
savings down the line. For example, life-long costs for palliative therapies have been 
calculated for Duchenne muscular dystrophy in several European countries (Figure 6).138 The 
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disease lasts decades, amounting to very high costs for the NHS. Even if economically 
convenient in comparison with life-long palliative − but expensive − therapies for 
regenerative medicine, a huge amount of money would be needed in a relatively short time, 
rather than being distributed over many years or even decades. 
 
While the market grows over the next few decades, it is useful to think of ways that 
regenerative medicine products can be made more affordable and cost-effective so that 
patients can benefit. Options include limiting prices using some form of price regulation; 
improving manufacturing infrastructure to reduce cost of goods; considering cost-
effectiveness issues at the early development stage to avoid pursuing interventions that are 
unlikely to ever be good value for money; and greater use of patient access schemes to share 
risks between companies and health services.  
 
 Given the personalised nature of regenerative medicine and high manufacturing costs, these 
therapies will probably need to be highly beneficial to patients (compared with current 
therapies) in order to be cost effective. Or else, they might seek to target diseases for which 
there are limited or no treatment options, where value for money may be easier to 
demonstrate.139 With this in mind, developers ought to undertake a realistic assessment of 
whether their technology will be reimbursed at a price sufficient to generate a competitive 
return. It should not be assumed technologies that make it to market will automatically be 
adopted and paid for at a profitable rate.140 One approach that has been considered for 
incentivising the production of technologies that meet population needs is value-based 
pricing. Here, prices are linked to the benefit a health care programme delivers, rather than 
the price suggested by manufacturers. 141 There have also been recent advances in methods 
for value-of-information analysis to assess the value of investing in research on innovative 
technologies such as regenerative medicine.142 Other novel approaches have been suggested 
with a view to identifying technologies that are good candidates for reimbursement. For 
example, the Value-Engineered Translation (VET) framework is an approach that could be 
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applied to regenerative medicine. VET was designed to evaluate candidate therapies for their 
potential to achieve market reimbursement, based on analyses of unmet need and the 
likelihood of clearing market access hurdles.143  
 
Regulation of stem cell therapies and regenerative medicine 
 
Regulation of clinical research is well established. What is less clear is whether existing 
regulation is fit for purpose in relation to new technologies, and whether those tasked with 
applying regulations understand new technologies sufficiently. Scientific advancements in 
the field of regenerative medicine happen frequently and legislation and regulation 
developed in an earlier era may not be adequate to address new challenges posed as 
technology advances. The knowledge and technical capabilities of the research community 
will always be ahead of that of legislators and regulators, and the process of developing 
legislation and regulation will always be slow, subject as it is to wider public discussion and 
debate. 
 
The core challenge for the ethics and regulation of cell therapies, as for other new 
technologies, then, is to appropriately balance the benefits against the risks. Doing so 
requires a clarification not only of the types and the size of the benefits that cell therapies 
could create, but also of contextual factors such as how the benefits will be distributed over 
the population, and the opportunity costs of providing the benefit. 
 
A robust and transparent system of laws and regulations is necessary and desirable. First, it 
exists to protect patients from unnecessary risk. But it also provides a framework to give 
investigators, funding bodies and commercial investors the confidence required to invest in 
the research and development required to bring innovative products to market. Where 
regulation is missing or weak, those who invest in and develop technologies are at risk of 
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unfavourable, unforeseen changes in the regulatory environment. This will discourage 
investment and ultimately be to the detriment of patients.  
 
Compliance with regulation does introduce costs to those developing new therapies. Where a 
regulatory system works well, costs are the minimum needed to achieve regulatory 
objectives. Where a system of regulation is overly burdensome and costly, this will 
unnecessarily deter investment − leading to potential losses both economically and in 
potential health gain of the population. In Europe, this may be particularly acute, as 
regulation will exist at national level as well as across nations. To address this problem a new 
committee was created within the European Medicinal Agency, the Committee for Advanced 
Therapies (CAT), whose members include working scientists who provide the requisite 
technical expertise. Still, navigating regulatory processes across multiple countries and 
jurisdictions will increase costs and introduce further risk to those looking to commercialise 
research.  
 
Currently, the number of human regenerative medicine clinical trials remains small. The US 
National Institutes of Health maintain a database of clinical trials involving human 
participants, accessible online at clinicaltrials.gov. As of June 2016, a search of this database 
(using the search term ‘regenerative medicine’) identified 188 registered studies. Of these, 84 
are open trials (those in set-up, or in recruitment stages), and 87 have been completed. A 
further 17 trials are listed as having ‘unknown status’. By comparison, for example, there are 
currently over 100 open trials of a single drug – adalimumab – a widely used biological 
therapy, the use of which shares certain characteristics with regenerative medicine (see 
below). 
 
However, if the same website is interrogated for “cell therapy”, more than 31,000 (thirty one 
thousand) trials are listed. Taking as examples just the subsection of trials registered in the 
areas of "muscular dystrophy” or “cystic fibrosis", 55 or 65 studies are listed, 
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respectively.  Several of these do not really describe the use of cells at all; of those remaining, 
many meet the characteristics of unproven cell therapies (e.g. unclear rationale for efficacy, 
insufficient data from in vitro studies, animal studies and safety studies in humans, 
inadequate information about patient consent and administration methods: see Srivastava et 
al, 2016 for a recent discussion of the topic).11 In addition, almost all lack supporting 
publications. Many studies therefore might well be categorised with the unregulated stem 
cell clinics market and cannot be considered to be on a par with rigorous trials by virtue of 
their presence on the website. This situation urgently calls for the creation of a novel register 
or sub-register, where trials are peer-reviewed and curated to guarantee a high clinical 
standard (see Recommendation “Better governance”). This issue is detailed below. 
 
Ethics  
 
In examining the ethics of cell therapies, it is the health benefits and harms of such therapies 
that should be the main focus, and a broad view could be taken of what could count as a 
health benefit or harm. Direct health benefits such as life extension or reduction in pain can 
be distinguished from indirect health benefits such as creating a regenerative medicine 
knowledge commons. Direct health benefits are relatively easier to measure, and often occur 
over a shorter term than indirect health benefits. Health risks and health harms have also 
been interpreted broadly here, to encompass not only direct morbidity and mortality, but 
also to include indirect factors such as undermining of trust in the healthcare system, 
violation of autonomy, and foregone benefits elsewhere in a healthcare system.  
 
Balancing benefits against risks 
As Hermansson and Hanso argue,144 risk management problems can be modelled as having 
three main parties: (1) those on whom the risk is imposed; (2) those who control the risk, 
and (3) those who benefit from the risk being taken. Risks are least ethically problematic 
where the same person fills all three roles – as when an experienced and knowledgeable 
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mountaineer takes on a challenging ascent. Risks are most ethically problematic where the 
risk-exposed neither benefit from their risk exposure nor can control their exposure to the 
risk – as when individuals are adversely affected by pollution from a poorly regulated 
factory. Judgements about the acceptability of risk also depend on the overall size of the 
benefit when compared to the risks. (See box. 3) 
This analysis provides a useful baseline understanding of the diverse ethical profiles of cell 
therapies. Direct benefits and harms should typically weigh more heavily than indirect risks 
and benefits, both because it is less certain that indirect benefits and harms will eventuate, 
and also because in cases of direct harms, the risk is less typically shared by the broader 
community and more usually concentrated on particular individuals. It is for this reason, 
perhaps, that the Declaration of Helsinki focuses on benefits and risks to individuals and 
groups involved in the research project, rather than the community more generally.145 
 
We will trace out this analysis through different points on the translational continuum 
between Phase I trials and routine medical practice. As therapies move along this 
continuum, direct risks will typically become better controllable, and as therapies shift from 
early phase to late phase trials and into routine clinical practice, there is an increasing 
expectation that the therapy will be directly beneficial to the individual patient. (See box. 4) 
As is discussed below, a well-functioning governance system would also ensure that the 
indirect risks (such as undermining of the social contract involved in research) are 
adequately controlled, and indirect benefits realised.  
 
There are two major ways in which the risks of cell therapies can be controlled: governance, 
and individual consent. In a broad sense, governance is a framework of incentives, 
professional standards, regulations, norms and social expectations oriented towards 
upholding rights and promoting the public interest. Informed consent supplements 
governance by allowing individuals to control their own risk on the basis of information 
provided to them. In cases of novel technologies, informed consent struggles to adequately 
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protect individual interests outside of a strong governance framework. Where the 
information available on risks and benefits is scanty or uncertain, it will be difficult for 
individuals to control their risks through informed consent alone.  
 
Different systems can give either more or less control to the patient through individual 
consent, and will have difference tolerances for paternalism (See Box. 5). No system should 
allow individuals unfettered freedom to consent to any procedure no matter what the risks or 
benefits are. It is helpful to distinguish between cases in which access to a therapy that is 
reasonably believed to be against a patient's best interest is denied because of an assumption 
that something has been deficient in the patient's decision-making process (soft 
paternalism), and cases in which access to a therapy is denied simply on the grounds that it 
is contrary to a patient's interest (hard paternalism). In general, hard paternalism is more 
difficult to justify – though there is an established medical practice of ruling out certain 
medical interventions on hard paternalistic grounds, such as surgery without good medical 
reason or where an intervention would be futile.146 Policy choices about paternalism need to 
take into account both the means by which paternalism is pursued, and also the extent to 
which the choices and actions interfered with are likely to fail to reflect a person’s 
autonomous will. 147 
An individual’s willingness to take a therapeutic risk will always be dependent on what that 
person anticipates might happen. Where novel therapies involve patients who have no other 
options for treatment and are desperate, the hope of a cure can make them highly vulnerable 
to wishful thinking and—where money is involved—vulnerable to false promises. Both 
research and clinical practice face difficult problems in this respect, with complex and 
disputed judgements about the role that hope should play in human life, and the conditions 
under which creating or sustaining ‘false hope’ is ethically problematic. These are important 
life choices that cannot simply be taken away from patients.148 But how best to reconcile the 
different values in play will vary according to local variation, with jurisdictions that place 
more weight on personal autonomy and responsibility giving the individual greater decision 
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making control than others, and this may mean tolerating false hope. There is no generic 
solution.  
 
 
 
In the rest of this section, we focus on two main areas of ethical contention: the source of 
cells to be used in cell therapies; and access to cell therapies. In both cases, we address these 
questions with an eye to the translational continuum between bench science, clinical trials 
and routine practice. 
 
The source of cells 
As discussed above, the cells to be used as the basis of cell therapies must either come from 
the same individual (autologous transplantation), or different individuals (allogeneic 
transplantation).  
 
When cell therapy requires donation from another individual, many of the ethical issues that 
are presented have extensive parallels with its early predecessors, bone marrow transplant or 
organ transplantation, although a number of commentators have pointed to the gendered 
bioeconomies of tissue procurement in the context of ESC.150 As with these earlier 
interventions, allogeneic transplants can be taken either directly from a patient's relatives, or 
be mediated via an international donor bank or sold commercially. Where the donor is a 
patient's relative, questions of risk, consent and voluntariness emerge: potential donors may 
be considered by other family members to be morally obliged to undergo what could be a 
moderate or major medical intervention – a small tissue biopsy, or an organ donation – and 
could face very negative reactions if, for whatever reason, he or she refuses to donate.  
 
This ethical complexity is reduced by the existence of donor banks, in which the patient is 
unlikely to know or meet the person who donates a tissue that could save his or her life. 
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International donor banks exist for bone marrow and blood but at least for now, not for 
other tissues, ESC or induced pluripotent stem cells (iPSC), though this has been considered 
as a real possibility, once therapies using these cells become a reality. It is also possible that 
the development of autologous therapies or, more remotely, of a universal donor cell, could 
provide a resolution for these challenges. 
 
The creation of international donor banks for ESC or iPSC raises a distinct set of policy 
questions and ethical concerns. For instance, whether they should be purely non-
commercial, or would it be ethically acceptable if a mixed economy of some private, and 
some publicly funded banks emerged? Would models of ethics and governance designed for 
existing donor banks or biobanks be broadly adequate for ESC or iPSC donor banks? Donors 
might well not be able to foresee how their cells are going to be used in the future, and so 
questions will arise (as with biobanks) about the ethical validity of broad consent in 
donation.151   
 
Ethical issues have been raised for example by the Catholic Church and other Christian 
groups in relation to the use of embryonic stem cells in particular, on the basis that their use 
offends the sanctity of life. The concern relates to the Catholic doctrine (see for example: the 
donum vitae, “Instruction on Respect for Human Life in Its Origin and on the Dignity of 
Procreation” (issued on February 22, 1987 by the Congregation for the Doctrine of the Faith) 
that human dignity and personhood arise at conception and not just (as human rights law 
suggests: Article 1 1948 UN Declaration on Human Rights) at birth,152, 153 and to the fact that 
the acquisition of embryonic stem cells requires the destruction of fertilised human eggs. On 
this basis, such cells are considered to already possess the moral status of a full human being 
and it would, therefore, be morally impermissible to use them for scientific research or 
therapeutic purposes. Similar debates have arisen in the context of the ethics of IVF, and are 
not distinctive to the ethics of regenerative medicine. Environmentalists such as Greenpeace 
have a separate ideological objection: that, as living entities, the patenting of cells derived 
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from human embryos should not be commercialised.  Although ethical debates of this nature 
continue to strongly influence developments in the US and certain European contexts, this 
issue will not be discussed in detail here.154  
 
A number of questions about the ownership and control of cell-lines also arise: Is a cell-line 
derived from me still my property? These questions predate current regenerative medicine, 
and even the human genome project. In fact, they go back at least as far as the emergence of 
experimental cell lines. As Skloot describes,155 the HeLa cell lines in current use by 
researchers derive from Henrietta Lacks in 1951. No consent was received at the time from 
Henrietta Lacks, and it was only 20 years later that family members became aware of the 
global usage of the cell line derived from her. The nature of their subsequent struggle for 
recognition revealed a wide gap between the regulatory concerns and the perceptions of her 
family about what should come back to them. The question of legal ownership of derived cell 
lines was further explored in “Moore v. Regents of California: 249 Cal. Rep. 494 (1988), 
Cal.Lex. 2858. (1990)”, where John Moore petitioned (in the end unsuccessfully) for a share 
of the proceeds of a cell line that had been created from his spleen.156 Both cases provide 
prescient examples of the likely on going tension between social innovation and social 
equality as Ruha Benjamin points out in her examination of stem cell initiatives in the US.157 
 
Under the current legal regimes within both the EU and the US, autologous cells are 
regulated similarly to allogenic cells. Both US and EU regimes thus reject the principle that 
someone who donates his/her own cells for therapeutic modification should be able to 
decide whether and how those cells are to be returned to him/her.  In the case of the US, the 
Code of Federal Regulations § 1271.3(d) was modified in 2005 to bring autologous cells 
under its remit. (A single word change was made: “[h]uman cells, tissues, or cellular or 
tissue-based products (HCT/Ps) means articles containing or consisting of human cells or 
tissues that are intended for implantation, transplantation, infusion, or transfer into another 
human recipient”, was changed to “…a human recipient”. While this change reflected 
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questions about whether autologous cells should be considered as a medicinal product not 
just a practice, others see this intervention as an expansion of the role of the state in the 
practice of medicine.158 The situation within the EU is complex, and there is some gap 
between the legal position contained in the European Tissue and Cell Directive (2004/23) 
and its two satellite directives (2006/17 & 2006/86), collectively referred to as the “EUTCD”, 
and the Advanced Therapy Medicinal Products Regulation (1394/2007) (“ATMP”) and what 
has been adopted by regulators. 
There is also diversity of regulatory regimes for stem cells in Europe within the limits set by 
the European Union Tissues and Cells Directives (EUTCD) and Advanced Therapy Medicinal 
Products (ATMP), and a complex landscape worldwide. While a thorough and complete 
analysis of all countries where research on stem cells is on going would be beyond the scope 
of this Commission, we will provide a few examples. With respect to the clinical use of stem 
cells, this is tightly regulated in many countries (for example in the EU, US, Japan, through 
EMA, FDA and Ministry of Health, Labour and Welfare, respectively), or subject to less or no 
regulation in a number of others, including India, where at present there are only provisional 
guidelines whose legal power is limited.159 In China the National Health and Family Planning 
Commission (NHFPC) has recently begun working with draft regulation for clinical research 
and applications that involve human stem cells,160 which though considered formal is 
currently flexible.  As discussed elsewhere, it is, however, nearly impossible to control the 
activity of private clinics that offer stem cell therapies without abiding by any regulation, a 
challenge which applies to virtually any country.  
In addition, upstream of any therapeutic use, there is significant variation with respect to 
research on human embryonic stem cells, reflective of religious and cultural contexts, as well 
as socio-economic conditions. Some European countries ban the in-country derivation of 
stem cell lines, but permit use of imported human embryonic stem cell lines for research 
(Italy), others have no specific legislation relating to stem cells research at all (Ireland), some 
ban all ES cell research (Lithuania), while others maintain a comprehensive and well-
established regulatory framework (UK, Spain).161 In the case of the US, on March 9, 2009, 
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President Barack Obama issued Executive Order 13505: Removing Barriers to Responsible 
Scientific Research Involving Human Stem Cells. This reversed a former prohibition on the 
supporting human ES research with federal funds. What will happen under the next 
President is yet to be seen.  More generally, bioconservative political parties may, for purely 
ideological reasons, attempt to enforce more restrictive policies on ES research, in the light 
of other recent signs indicating anti-scientific attitudes.    
 
 
Access to therapies 
 There are four ways in which patient access to stem cell and regenerative therapies can be 
obtained. First, and most straightforwardly, when a therapy has been tested and received 
marketing approval for the indication for which the clinical team intends to use it.  Second, 
in the context of a clinical trial. Third, through permitted non-research access to a treatment 
that does not have marketing approval for that indication. This would include “specials” and 
the hospital exemption within the EU, and also off-label or compassionate use. Fourth and 
more critically, through direct recruitment (usually through the internet) from commercial 
entities whose activity is not scrutinized/approved by any regulatory body. 
 
Access to cell therapies via clinical trials  
Perhaps the most difficult questions for access to experimental interventions are whether 
there should be a maximum level of acceptable risk (even when validly consented to; raising 
again the issue of hard paternalism highlighted earlier); and what the response should be to 
severe adverse events in clinical trials. For example, it is interesting to speculate whether 
under today’s regulations, BMT would have emerged as a consolidated therapy. The first 
patients to be treated invariably died after the transplant, but the persistence of its pioneers 
in searching for the causes of its failure, their quest to better understand transplant 
immunology, and the lack of pressure to move rapidly to market allowed this procedure to 
progressively develop into a safe and life-saving therapy. More recently, the few, though 
51 
 
tragic, deaths that have since occurred in gene therapy trials led to their cessation and 
stimulated further research (for example on vector integration sites) that now ensure higher 
safety. While on the one hand increasing controls prohibitively raises costs to the point of 
making it very difficult for academics to conduct even early Phase (I or IIa) trials; on the 
other, complete deregulation would legitimise the practices of stem cell clinics offering 
unproven therapies on the principle of free choice.  
 
The next few years are likely to bring a fresh iteration of the ‘free to choose’ paradigm, 
leading to clashes between medical and business motives pushing against the ‘strict and 
expensive rules’ that the FDA and EMA currently defend. The key challenge for regulatory 
agencies will be to find a path that reconciles rigorous controls and economically affordable 
clinical protocols. Perhaps the most important issue from the point of view of risk 
assessment is the relevance of the indirect benefits of this research for the creation of a 
knowledge commons.  
 
For many of the conditions for which cell therapies are now being developed, enrolment in a 
clinical trial provides the only source of hope for patients. This means that selection of 
patients raises significant ethical issues. Some diseases are so rare that essentially all eligible 
patients can be treated with no need for selection. However, the most common among the 
rare diseases (for example Haemophilia or Cystic Fibrosis) affect populations of patients who 
far exceed the number eligible for experimental trials, which are usually limited to a few 
patients, both for safety and economic reasons. In general, most patients affected by serious 
diseases are inclined to accept the risks of experimental therapies in exchange for the hope, if 
not of a cure, then simply of a small improvement, a step towards treatment that may benefit 
other patients after them. Very often, selection is based on objective criteria (for example 
age, type of mutation, severity, and availability of an HLA-compatible donor).  
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In cases where more patients are eligible than the few who are normally enrolled, selection 
poses both medical and ethical issues. On the one hand it could be argued that the chance of 
benefit is balanced by the unpredictability (within the limits of good pre-clinical work: see 
Recommendation “Better science”) of a 'first in man’ therapy. The problem is that for those 
awaiting the next trial, the disease may progress to a stage when they would no longer be 
eligible for the subsequent enrolment. There is no easy solution for this issue. This is 
exacerbated by the fact that, in nearly all cases, the mere mention of the words ‘stem cells’ is 
sufficient to tempt patients (or parents, in the case of children) to try unproven, 
experimental treatments. Although the results of any trial carry uncertainties, the use of such 
‘therapies’ also happen outside of the structure of a regulated health system, and come a high 
financial (out-of-pocket) cost. Such patient behaviour is fully understandable when the 
alternative is imminent, rapid disease progression towards an inevitably fatal end. It is 
important to differentiate between carefully designed and conducted clinical trials (which 
should not require a patient to bear any financial costs) and those in which private stem cell 
clinics are essentially taking advantage of patients’ vulnerability. 
 
Permitted non-research usage of therapies that do not have marketing 
authorisation for that indication 
 
US and EU regulatory regimes differ when it comes to access to therapies that have not 
received marketing approval. In the EU, the Medicinal Products Directive only applies to 
products that are placed on the market, and explicitly allows access to therapies that have 
not received marketing approval through the “hospital use” and “specials” exemptions. 
 
Access to unlicensed medicinal products outside of a clinical trial has until very recently been 
more restricted in the US. Such access was allowed only under the Expanded Access to 
Investigational Drugs for Treatment programme, which requires FDA approval and can be 
used only for products that are currently being tested somewhere in a clinical trial, and 
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where it can be shown that expanded access would not interfere with “the initiation, conduct, 
or completion of clinical investigations to support marketing approval”.  Since 2014, more 
than half of US states have passed “right to try” laws, laws, which allow terminally ill patients 
to receive experimental therapies that have passed Phase I, without seeking FDA approval. 
 
These regulations attempt to balance considerations of safety and efficacy with meeting the 
needs of patients who require urgent medical intervention and who have no other avenues 
available to them.  
 
Where patients are in dire straits and where there is sufficient evidence to indicate that the 
benefits are proportional to the risks for the individual patient, such exemptions do have a 
role to play. Furthermore, the idea of adaptive licensing should be explored more fully, in 
addition to the use of these exemptions.  
 
A social contract is needed 
The mechanisms for regulating risk in research are only part of the framework for securing 
desired innovations in cell and gene therapies. We also need to revisit the social contract on 
which medical progress is based.   The social contract is used here to denote the construction 
of mutually beneficial alignments of interests to ensure that science develops in conjunction 
with social benefit rather than in opposition to it. It goes beyond the private contract 
between patient and clinician/scientist, which is contained in rules of informed consent and 
malpractice liability. It incorporates the idea of the social licence, by which scientists are 
permitted to research. However, the social licence is more passive than the arrangement that 
is needed if cell and gene therapy is to be harnessed for mainstream use. Licences require the 
licensees (researchers) to behave in ways that prevent their permission to operate being 
withdrawn, but they raise only very limited expectations on licensors (the public). As we are 
at an early stage of the path through which cell and gene therapies will transition from 
experimental therapy to mainstream practice, a good governance framework needs to 
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increase the sense of mutuality between the public and scientists and also to enhance the 
sense there is a common project that will take time to come to fruition so that science and 
wider society need to commit to work in conjunction for a period if the benefits are to be 
secured. The use of the term 'contract' rather than 'licence' is used to capture these needs for 
mutuality and endurance.  
To sustain their licence to practise research in this area, scientists need to demonstrate that 
they can be trusted. This requires competence, addressed by our recommendations in 
respect of better science. It also involves openness, recognising the public stake in the future 
that therapies may make available, acknowledging and addressing concerns that are raised.  
Trustworthiness is partly based on transparency, making the successes and failures 
accessible to researchers and the public (with appropriate respect for patient privacy). The 
social licence for research also requires accountability. This takes a range of forms. The most 
important is the need for the scientific community to accept responsibility for giving a 
publicly available, accurate account of the state of the science. Nevertheless, the continuation 
of social licence for research requires reassurance that scientists who disregard their public 
responsibilities can be held to account.  
Issues of liability to individual patients for mishaps and misconduct are a subset of 
accountability. These will necessarily be addressed within specific regulatory systems and 
cannot be specified in detail. Informed consent will remain vital, but given the propensity to 
hype and the high probability that patients using emerging cell and gene therapies will have 
few options, there is a collective interest in raising the quality of information that patients 
receive. While informed consent is primarily a private matter for patients, it could be better 
supported if the stewards of a register specific to these therapies used it to provide accurate 
information about the uncertainties, success and known risks of therapies that are included. 
Public engagement and trust 
 
The way that research groups, their institutions and funders undertake public engagement 
about medical research suggests that public engagement is perceived and conducted in two 
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ways.  
Most commonly, it refers to activities that would just as easily be defined as dissemination 
and publicity, albeit now sometimes in a more interactive format at publication stage (such 
as podcasts, lay summaries and lead author Q&As). But public engagement is a much more 
confused and patchy business. The benefits of targeted patient engagement exercises for 
patient participation in research have been well observed (World Health organisation 
2008).162 To adhere to the guidelines of the International Society for Stem Cell Research 
(ISSCR) and the International Society of Cell Therapy (ISCT), requesting that patients fully 
understand the risk/benefit balance and the nature of the trial they in which they are 
participating, researchers need to engage quite extensively with potential trial participants. 
10, 11, 163 However, beyond targeted patient interactions and publicity initiatives, it is not clear 
what researchers should do. Reports of wider benefits and the effectiveness of more general 
engagement programmes have been found to be mixed, and accompanied by concerns that 
extensive engagement would require significant resources, and that in the absence of these it 
can become tokenistic 12 This is not to say there’s a lack of interest or concern. When 
surveyed, medical researchers have given a range of ethical, moral, political and pragmatic 
arguments for engaging the public in general and patients in particular 164. As indicated 
throughout this commission report, the case for engagement in stem cell research is strong. 
The continued and unavoidable mismatches between public expectation and delivery of 
applications, the fact that regulatory conditions (whatever the level of complexity) can be 
easily ignored in countries in which no regulations exist and private clinics attract hopeless 
patients for large amounts of money – all create the conditions for public 
controversy.  However, regardless of views held on the usefulness and desirable extent of 
public engagement, it is clear that extensive deliberative exercises are not becoming the 
norm even in those countries and research areas for which some funding for them is 
available, never mind globally. 
  
The perception that public engagement options boil down to a choice between an ideal of an 
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expensive, extensive deliberative programme on the one hand, or tokenistic activity of 
uncertain value on the other is creating a blind spot. There are much more prosaic and 
straightforward activities that researchers are able to undertake themselves at minimal cost. 
Stem cell research can be contextualized and informed by public discussions without 
extensive direct participation. A review of the public discourse - including media, political, 
interest group and regulatory discussions should form part of the early development of 
research programmes. A pre-emptive analysis (which may well include direct engagement, 
testimony and consultation, but it is not limited to those) enables researchers to see where 
their questions overlap with the explicit and implicit questions posed in public discussions. 
This would open up the potential for increased public discourse and correctives to 
misapprehensions about previous work in the field, the regulatory context of the research, its 
potential applications and the likelihood that they will be realized in relation to patient and 
carer expectations. 
 
 Conclusions 
 
Those engaged in pure research justifiably bridle when unrealistic outcomes are presented as 
a tactic for swaying the use of limited public funds or of recruiting private funds to 
experimental and unproven procedures—whether that be for avian flu modelling, for Ebola 
preparedness, or for patients in wheelchairs demanding the latest experimental treatment 
for Duchenne muscular dystrophy. But the problems of regulation are not only limited to 
controlling irresponsibility on the part of those lobbying to direct limited funding towards 
their work. Strict, though necessary regulation often prevents or makes it extremely difficult 
for academics and small companies to take risks related to conducting even Phase I trials 
(see Recommendation “Better science”), let alone Phase II and beyond. Regulatory bodies 
are aware of the problem and encourage researchers to interact very early in order to provide 
advice. Through such guidance it is hoped, as far as possible, that costs related to potentially 
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unnecessary controls will be reduced, without compromising on rigorous quality control of 
the medicinal product under development. 
 
Looking across the landscape of scientific discovery, it is acknowledged that those who take 
risks in their work make some of our most important discoveries. However, this is justifiably 
less the case where human lives are concerned. The absence of innovation in medicine is, 
therefore, just as much a problem in surgical innovation as it is in experimental stem cell 
therapies. When clinical experimentation explores unknown pathways, possibly even risking 
the life of patients, controls must be as stringent as possible. 
 
The problem is only exacerbated with respect to illnesses in which animal testing has only 
limited applicability, or may even be impossible. As a public health problem across the globe, 
Dengue fever, for instance, grows alarmingly in part because vaccine testing is only possible 
with human subjects. So, while we await yet more failed attempts at a vaccine, the disease 
spreads at frightening speed.  
 
Though regenerative medicine is not generally subjected to the pressures involved in 
response to infectious diseases, it does suffer from the same problems, in that the testing of 
experimental therapies relies on human subjects. This is only made more complex by the 
personalization of those therapies. In fact, because so many new developments are explored 
at the level of personalized medicine, the problem is, if anything, more acute. 
 
And there is another looming problem: that of global governance. Though guidelines exist 
and are globally recommended, there will always be places where otherwise prohibited 
practices are allowed. The fact is, even with common efforts to expedite reviews and optimize 
regulation, there is simply no way to compete with an absence of regulation. Renegade 
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surgeons sometimes boast of their enhanced outcomes based on the freshness of organs 
culled from places they dare not ask about.165  
 
So the question of what to do about the desperate sufferer who mortgages a house for an 
experimental treatment that turns out to be little more than saline is one that we need to face 
boldly. Again, if one looks at transplantation practices, the reality could not be clearer. Of the 
roughly 9000 individuals awaiting transplants in the UK, some 1500 are of South Asian 
descent; yet there are only about 150 donors annually. For those who choose to go abroad, 
the choice can result in a grim outcome. Indeed, some 40% of those transplants will fail, or 
kill the patient outright, within a few years. 
 
We must, therefore, be especially alert to the need to develop new ways of protecting those 
who name and shame poor, if not unethical science. This is important when set against the 
real legal and other threats they face from companies that do not meet regulator’s conditions 
of strict oversight, and the enforcement of laws where they exist. At the same time, 
expedition is essential for companies and academics to remain competitive and move the 
field forward, balancing as much as possible, risks, costs and potential benefits. How we 
proceed in this new global terrain may be our biggest challenge of all.  
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Box. 1  
What do we mean by Regenerative Medicine and, more specifically, Cell and 
Gene Therapies and Tissue Engineering?  
 
Regenerative Medicine is an emerging medical endeavour aimed at regeneration via small 
molecule drugs, biologics, medical devices and/or cells and genes.  It aims to replace or 
repair human cells and/or regenerate tissue or organs to restore normal function. 
Cell Therapy is a developing medical technology based upon delivery of cells as medicines for 
a growing variety of the clinical indications. Likewise, gene therapy is based upon delivery of 
genes as medicines. Delivery may be direct into patient tissues (in vivo gene therapy) or cell 
mediated (ex vivo gene therapy - a combination of cell and gene therapy). Gene therapy is 
not an exclusive domain of regenerative medicine, as most ongoing gene therapy trials are 
for cancer treatments. Finally, tissue engineering is based upon implantation of artificial or 
reconstructed whole organs or tissues. When these implants contain patient or donor cells, 
tissue engineering could be considered a special form of cell therapy. While the terms “cell or 
gene therapy” have entered common language, with few exceptions, they are experimental 
therapies rather than standard/consolidated ones. 
 
Box. 2 Cost-effectiveness of treatments 
Many of the therapies discussed here are likely to have significant costs when ultimately 
delivered to patients. But for many of the conditions being treated, these costs may be off-set 
by potential savings over the longer run, by reducing the need for expensive health and social 
care in the long-term. Many may also be life-saving, and/or lead to significant improvements 
in population and individual health. The costs of regenerative medicine ought to be balanced 
against the cost savings and improvements in health. Consider the potential for 
revolutionary treatments for chronic and life-limiting illnesses, such as Duchene muscular 
dystrophy or Crohn’s disease. Such illnesses are characterised by high, recurring costs of care 
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and low health-related quality of life. Therapies that improve such conditions could lead to 
significant reductions in costs of other care, as well as significant improvements in length of 
life, health and wellbeing. Any treatment – even a very expensive treatment – has the 
possibility to be cost-effective where the offset costs of continuing care and the gain in health 
are sufficiently large.   
 
Box. 3 Balancing benefits and risks 
 
A bone marrow aspirate, a skin or muscle biopsy are minor surgeries and essentially free of 
risk in comparison with huge potential benefit that may derive from their use. This is the 
large majority of cases. A biopsy in the heart or an area of the brain should be considered 
more carefully because of the inherent risk of damaging one part of the body to fix another. 
Moreover, improper cell manipulation may add another level of risk. 
 
 
Box. 4: Different translational stages have different risk profiles 
• Phase I clinical trials do not aim to benefit the individuals taking part in them. 
Information available about risks involved in trials may be too scant to make the risk 
easily appreciable by participants. 
• Phase II and III trials (for small and large cohorts of patients, respectively) aim to benefit 
individuals taking part along with the goal of generating new knowledge. Increased safety 
information from earlier trials makes risks more appreciable by participants. 
• Routine practice has the benefit to individual patients as its primary goal. The fact that a 
therapy has passed through the regulatory system and has been given marketing approval 
gives patients some confidence that the benefits of the therapy will in general be at least 
proportional to its risks. Increased information from clinical trials and from routine use of 
therapy makes it much easier for patients to be able to regulate their risk through 
informed consent. 
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• Unregulated and uncontrolled stem cell therapies have a particularly problematic risk 
structure. In these cases, the risks of the therapy (both of medical harm, and financial 
loss) fall on patients, whilst the main beneficiaries are those who provide the therapies. In 
addition, such therapies take advantage of lax regulatory environments of certain 
countries or simply act outside of any regulation. There are no mechanisms to ensure that 
information is accurate and complete, so neither regulation, nor informed consent, 
provides an adequate ability to balance the risks.  
 
 
 
Box. 5: Paternalism 
Paternalism in general consists in interfering with the liberty or autonomy of individuals in 
order to benefit them without their consent. In cases where the choices or actions that are 
beneficently interfered with are substantially non-autonomous, this is soft paternalism. 
Where the beneficent intervention interferes with choices or actions even when they are fully 
autonomous, informed and voluntary this is hard paternalism. The distinction between hard 
and soft paternalism refers to the extent to which the choices or actions interfered with 
authentically embody the individual’s autonomous will. This is a separate question from the 
coerciveness or otherwise of the means employed to interfere with these choices.137 Policy 
choices about paternalism thus need to take into account both the means by which 
paternalism is pursued, and also the extent to which the choices and actions interfered with 
are likely to fail to reflect a person’s autonomous will.135  
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Figure and Table legends 
 
Figure 1: A simplified scheme of cell and gene therapy. 
 
Figure 2: Landmark steps in regenerative medicine. Original papers 14-22 are listed in the  
Reference section 
 
Figure 3: Corneal restoration. (A) Left eye (at admission) of a 42 year-old patient who had 
total limbal stem cell deficiency due to acid burn. (B) eye of the patient at the last follow-up, 
6 years after graft. (Reprinted with permission from Regen. Med).  29-31 
 
Figure 4: iPSC technology contributes to disease modeling and drug screening (A), cell 
transplantation (B) and clinical trials (C) (Reprinted with permission from EMBO J.). 42 
 
Figure 5: A scheme of the gene therapy clinical trial for ADA-SCID. CD34+ cells are collected 
from the patient’s bone marrow, transduced with a viral vector expressing ADA and, after 
mild myeloablation, re-infused into the same patient. (Reprinted with permission from 
Immunologic Research).  83 
 
Figure 6. Annual costs of Duchenne Muscular Dystrophy (DMD).  The mean per-patient 
annual direct cost of illness as estimated in different countries. (Reprinted from Neurology). 
138 
 
Table 1:  Summary of clinical applications of tissue engineering (at the date of submission). 
PLCA: poly-carpolactone; PLA: poly-lactic acid; PGA: plyglycolic acid; PLGA: poly-
lacticglycolic acid). 115, 120-123 
 
 
 
	  	  	  	  	  	  	  	  
Healthy 
donor 
:Healthy cell :Diseased cell 
Ex vivo 
gene 
therapy 
:Genetically  
corrected cell 
Cells spared by  
the disease  
:Viral vector 
In
 v
itr
o 
ex
pa
ns
io
n 
In vitro expansion 
In vivo gene 
therapy Donor cell 
therapy 
Patient 
Blood 
transfusion 
	  
Vertebrate 
cloning 
	  
Skin 
transplant 
 
	  
Mammalian 
cloning 
	  
Induced 
pluripotent 
stem cells 
	  
Bone 
marrow 
transplant 
	  
Embryonic 
stem cells 
Gene 
therapy 
	  
Human 
embryonic 
stem cells 
	  
1874 
BMJ 
1957 
NEJM 
1958 
Nature 
1981 
PNAS 
1984 
NEJM 
1993 
HGT 
1997 
Nature 
1998 
Science 
2006 
Cell 




Organ 
Scaffold Cells Patient 
Number 
Follow
-up 
Results Ref. 
Type Size Type Number 
Bronchus 
Decellularised 
trachea 
7 cm 
Epithelial cells   1*106/mL 
1 
4 
months 
Normal mechanical properties and appearance of 
graft, improved quality of life, no 
immunosuppression 
120 
Chondrocytes   1*106/mL 
Trachea 
(Whole) 
Decellularised 
trachea 
7 cm 
Epithelial cells 
Epithelial cells 
2.5*108
Patches 
1 2 years Normal CT scan, appropriate growth, patient well 121  
Pulmonary 
artery 
PCLA-PLA 
matrix with 
PGA fibers 
2 cm 
Smooth muscle 
cells 
  12*106 1 
7 
months 
Graft patent on angiography, no occlusion, no 
aneurysm, patient well 
122  
Bladder 
Collagen 
matrix or 
collagen-PGA 
matrix 
70 - 
150 
cm2 
Urothelial cells 
50*106/cm3 
7 
46 
months 
Volume and compliance increase, preservation of 
renal function, adequate structural architecture 
and phenotype 
123 
Smooth muscle 
cells 50*106/cm3 
Urethra 
PGA-PLGA 
matrix 
5 cm 
Epithelial cells   1*107/mL 
4 
71 
months 
Maximum urinary flow rate 27.1 mL/s, no 
strictures, normal architecture  
(biopsy, 3 months) 
115 Smooth muscle 
cells 
  1*107/mL 
Chondrocytes   1*106/mL 
